import { ref } from "vue";
import { handleViteImages } from "@/utils";

export const releases = ref([
  {
    id: 20,
    type: "news",
    title: `Meet OBiO Technology at ASGCT 2024! May 7th to 11th`,
    time: "April 27th 2024",
    img: handleViteImages("uploads/image/20240427/Picture1.png"),
    subhead: "",
    content: "We are looking forward to ASGCT in Baltimore and excited to see you there! You’re invited to stop by OBiO Tech booth #1644. We will present 9 posters. Among these presentations are three self-developed patented achievements, four notable advancements in process optimization, and two cutting-edge technology introductions.",
    html: `<div class="Insights-detail-text text">
    <img src="${handleViteImages("uploads/image/20240427/Picture1.png")}" alt="" class="center"/>
    <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:115%;font-size:16px;font-family:"Aptos",sans-serif;text-align:center;'><br></p>
    <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:normal;font-size:16px;font-family:"Aptos",sans-serif;text-align:center;'><strong><span style='font-size:32px;font-family:"Calibri",sans-serif;color:#0070C0;'>F</span></strong><strong><span style='font-size:32px;font-family:"Microsoft YaHei",sans-serif;color:#0070C0;'>ocus</span></strong><strong><span style='font-size:32px;font-family:"Calibri",sans-serif;color:#0070C0;'>-Acceleration-Standardization-Team</span></strong></p>
    <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:normal;font-size:16px;font-family:"Aptos",sans-serif;text-align:center;'><strong><span style='font-size:24px;font-family:"Calibri",sans-serif;color:#0070C0;'>Our FAST Commitment to Accelerate Your Success</span></strong></p>
    <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:115%;font-size:16px;font-family:"Aptos",sans-serif;'><span style='font-size:19px;line-height:115%;font-family:"Verdana",sans-serif;color:black;background:white;'>We are looking forward to ASGCT in Baltimore and excited to see you there! You&rsquo;re invited to stop&nbsp;</span><span style='font-size:19px;line-height:115%;font-family:"Verdana",sans-serif;color:#0070C0;background:white;'>by <strong>OBiO Tech booth #1644</strong></span>.</p>
    <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:115%;font-size:16px;font-family:"Aptos",sans-serif;'><span style='font-size:14px;line-height:115%;font-family:"-apple-system",serif;background:white;'>&nbsp;</span></p>
    <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:115%;font-size:16px;font-family:"Aptos",sans-serif;'><span style='font-size:19px;line-height:115%;font-family:"Verdana",sans-serif;color:black;background:white;'>We will present&nbsp;</span><strong><span style='font-size:19px;line-height:115%;font-family:"Verdana",sans-serif;color:#0070C0;background:white;'>9 posters</span></strong>. <span style='font-size:19px;line-height:115%;font-family:"Verdana",sans-serif;color:black;background:white;'>Among these presentations are three self-developed patented achievements, four notable advancements in process optimization, and two cutting-edge technology introductions.&nbsp;</span></p>
    <img src="${handleViteImages("uploads/image/20240427/Picture2.png")}" alt="" class="center" />
    <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:115%;font-size:16px;font-family:"Aptos",sans-serif;'><span style='font-size:19px;line-height:115%;font-family:"Verdana",sans-serif;color:black;background:white;'>These milestones exemplify OBiO Technology&apos;s significant strides in the gene therapy domain, enhancing vector yield and efficiency, refining therapeutic processes, and driving down production costs.</span></p>
    <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:115%;font-size:16px;font-family:"Aptos",sans-serif;'><span style='font-size:19px;line-height:115%;font-family:"Verdana",sans-serif;color:black;background:white;'>&nbsp;Our innovative solutions offer dependable and cost-effective production methods for gene therapy, propelling forward clinical projects in gene and cell therapy.&nbsp;</span></p>
    <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:115%;font-size:16px;font-family:"Aptos",sans-serif;'><span style='font-size:19px;line-height:115%;font-family:"Verdana",sans-serif;color:black;background:white;'>Our experts are ready to share how our comprehensive viral vector platform accelerates development timelines, de-risks manufacturing, and provides the performance and product quality needed for your success, with a lower cost.&nbsp;</span></p>
    <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:115%;font-size:16px;font-family:"Aptos",sans-serif;text-align:center;'><br></p>
    <a href="https://www.linkedin.com/feed/update/urn:li:activity:7187104691195985921"><img src="${handleViteImages("uploads/image/20240427/Picture3.png")}" alt="" class="center" /></a>
    <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:115%;font-size:16px;font-family:"Aptos",sans-serif;text-align:center;'><br></p>
    <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:115%;font-size:16px;font-family:"Aptos",sans-serif;'><span style='font-size:19px;line-height:115%;font-family:"Verdana",sans-serif;color:black;background:white;'>&nbsp;</span></p>
    <img src="${handleViteImages("uploads/image/20240427/Picture4.png")}" alt="" class="center" />
    <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:115%;font-size:16px;font-family:"Aptos",sans-serif;'><span style='font-size:19px;line-height:115%;font-family:"Verdana",sans-serif;color:black;background:white;'>Mr. Javier Jia Guo, CEO of OBiO Technology, expressed, &quot;We are delighted to continue our legacy of excellence at the ASGCT conference! OBiO Technology will participate with utmost enthusiasm and innovative prowess, showcasing our latest achievements in gene and cell therapy. Our nine presentations, featuring self-developed patented achievements, process optimization breakthroughs, and technology introductions, epitomize our commitment to relentless innovation and collaborative problem-solving. They also underscore our significant progress in enhancing yield efficiency, streamlining production processes, and driving cost efficiencies. OBiO Technology remains steadfast in its forward-looking technological layout and continuous improvement of service capabilities, contributing to the rapid advancement of the gene and cell therapy industry.&quot;</span></p>
    <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:115%;font-size:16px;font-family:"Aptos",sans-serif;'>&nbsp;</p>
    <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:115%;font-size:16px;font-family:"Aptos",sans-serif;text-align:center;'><br></p>
    <a href="https://www.youtube.com/@obiotechnology"><img src="${handleViteImages("uploads/image/20240427/Picture5.png")}" alt="" class="center"/></a>
    <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:115%;font-size:16px;font-family:"Aptos",sans-serif;'><br></p>
    <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:115%;font-size:16px;font-family:"Aptos",sans-serif;'><strong><span style="font-size:24px;line-height:115%;">&nbsp;</span></strong></p>
    <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:115%;font-size:16px;font-family:"Aptos",sans-serif;'><span style='font-size:19px;line-height:115%;font-family:"Verdana",sans-serif;color:black;background:white;'>OBiO Technology leads the way in gene and cell therapy as a pioneering Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO), dedicated to providing comprehensive solutions.</span></p>
    <img src="${handleViteImages("uploads/image/20240427/Picture6.png")}" alt="" class="center" />
    <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:115%;font-size:16px;font-family:"Aptos",sans-serif;text-align:center;'><br></p>
    <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:115%;font-size:16px;font-family:"Aptos",sans-serif;'><span style='font-size:19px;line-height:115%;font-family:"Verdana",sans-serif;color:black;background:white;'>&bull; &nbsp; &nbsp; &nbsp;Our state-of-the-art 830,000 sq.ft facility ensures global supply excellence.</span></p>
    <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:115%;font-size:16px;font-family:"Aptos",sans-serif;'><span style='font-size:19px;line-height:115%;font-family:"Verdana",sans-serif;color:black;background:white;'>&bull; &nbsp; &nbsp; &nbsp;Specializing in vectorology studies, functional genomics, and process and analytics development, we ensure Investigational New Drug (IND) readiness and support all phases of clinical and commercial manufacturing.</span></p>
    <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:115%;font-size:16px;font-family:"Aptos",sans-serif;'><span style='font-size:19px;line-height:115%;font-family:"Verdana",sans-serif;color:black;background:white;'>&bull; &nbsp; &nbsp; &nbsp;Guided by our mission to &quot;Enable Gene Therapy for Better Lives,&quot; we prioritize delivering top-tier services worldwide.</span></p>
    <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:115%;font-size:16px;font-family:"Aptos",sans-serif;'><span style='font-size:19px;line-height:115%;font-family:"Verdana",sans-serif;color:black;background:white;'>&bull; &nbsp; &nbsp; &nbsp;From laboratory to clinic, we continuously advance your products, making a positive impact on populations worldwide.</span></p>
    <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:115%;font-size:16px;font-family:"Aptos",sans-serif;'><span style='font-size:19px;line-height:115%;font-family:"Verdana",sans-serif;color:black;background:white;'>&bull; &nbsp; &nbsp; &nbsp;Our unwavering commitment ensures the delivery of high-quality CDMO services across the preclinical, IND, clinical, and commercial stages.</span></p>
    <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:115%;font-size:16px;font-family:"Aptos",sans-serif;'><span style='font-size:19px;line-height:115%;font-family:"Verdana",sans-serif;color:black;background:white;'>&bull; &nbsp; &nbsp; &nbsp;Our expertise spans plasmids, mRNA, AAV, LVV, Ad viral vectors, cell therapy (CAR-T, NK, Treg), as well as cutting-edge technologies like inducible viral vector packaging, ultralow endotoxin processes, and tissue-specific AAV variants.</span> <span style='font-size:19px;line-height:115%;font-family:"Verdana",sans-serif;color:black;background:white;'><br></span></p>
    <a href="https://obio-tech.com/cdmo"><img src="${handleViteImages("uploads/image/20240427/Picture7.png")}" alt="" class="center" /></a>
    <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:115%;font-size:16px;font-family:"Aptos",sans-serif;'><br></p>
    <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:115%;font-size:16px;font-family:"Aptos",sans-serif;'><span style='font-size:19px;line-height:115%;font-family:"Verdana",sans-serif;color:#0070C0;background:white;'>Your Trustful Partner in Research and Manufacturing for Gene and Cell Therapy</span></p>
    <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:115%;font-size:16px;font-family:"Aptos",sans-serif;'><span style='font-size:19px;line-height:115%;font-family:"Verdana",sans-serif;color:#0070C0;background:white;'>&nbsp;</span></p>
    <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:115%;font-size:16px;font-family:"Aptos",sans-serif;'><span style='font-size:19px;line-height:115%;font-family:"Verdana",sans-serif;color:#0070C0;background:white;'>Phone: +1 408 422 9864</span>&nbsp;</p>
    <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:115%;font-size:16px;font-family:"Aptos",sans-serif;'><span style='font-size:19px;line-height:115%;font-family:"Verdana",sans-serif;color:#0070C0;background:white;'>Email: OBiO.US@obiosh.com</span></p>
    <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:115%;font-size:16px;font-family:"Aptos",sans-serif;'><span style='font-size:19px;line-height:115%;font-family:"Verdana",sans-serif;color:black;background:white;'>&nbsp;</span></p>
    <div><a data-v-4896eafd="" href="https://www.linkedin.com/company/41870372" aria-label="Company LinkedIn"><svg data-v-4896eafd="" class="svg-inline--fa fa-linkedin fa-2xl footer-icon" aria-hidden="true" focusable="false" data-prefix="fab" data-icon="linkedin" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 448 512"><path class="" fill="currentColor" d="M416 32H31.9C14.3 32 0 46.5 0 64.3v383.4C0 465.5 14.3 480 31.9 480H416c17.6 0 32-14.5 32-32.3V64.3c0-17.8-14.4-32.3-32-32.3zM135.4 416H69V202.2h66.5V416zm-33.2-243c-21.3 0-38.5-17.3-38.5-38.5S80.9 96 102.2 96c21.2 0 38.5 17.3 38.5 38.5 0 21.3-17.2 38.5-38.5 38.5zm282.1 243h-66.4V312c0-24.8-.5-56.7-34.5-56.7-34.6 0-39.9 27-39.9 54.9V416h-66.4V202.2h63.7v29.2h.9c8.9-16.8 30.6-34.5 62.9-34.5 67.2 0 79.7 44.3 79.7 101.9V416z"></path></svg></a>&nbsp;
    <a data-v-4896eafd="" href="https://www.youtube.com/@obiotechnology" aria-label="Company YouTube"><svg data-v-4896eafd="" class="svg-inline--fa fa-youtube fa-2xl" aria-hidden="true" focusable="false" data-prefix="fab" data-icon="youtube" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 576 512"><path class="" fill="currentColor" d="M549.655 124.083c-6.281-23.65-24.787-42.276-48.284-48.597C458.781 64 288 64 288 64S117.22 64 74.629 75.486c-23.497 6.322-42.003 24.947-48.284 48.597-11.412 42.867-11.412 132.305-11.412 132.305s0 89.438 11.412 132.305c6.281 23.65 24.787 41.5 48.284 47.821C117.22 448 288 448 288 448s170.78 0 213.371-11.486c23.497-6.321 42.003-24.171 48.284-47.821 11.412-42.867 11.412-132.305 11.412-132.305s0-89.438-11.412-132.305zm-317.51 213.508V175.185l142.739 81.205-142.739 81.201z"></path></svg></a>&nbsp;
    <a data-v-4896eafd="" href="https://www.facebook.com/profile.php?id=61555811491695" aria-label="Company Facebook"><svg data-v-4896eafd="" class="svg-inline--fa fa-facebook fa-2xl" aria-hidden="true" focusable="false" data-prefix="fab" data-icon="facebook" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512"><path class="" fill="currentColor" d="M512 256C512 114.6 397.4 0 256 0S0 114.6 0 256C0 376 82.7 476.8 194.2 504.5V334.2H141.4V256h52.8V222.3c0-87.1 39.4-127.5 125-127.5c16.2 0 44.2 3.2 55.7 6.4V172c-6-.6-16.5-1-29.6-1c-42 0-58.2 15.9-58.2 57.2V256h83.6l-14.4 78.2H287V510.1C413.8 494.8 512 386.9 512 256h0z"></path></svg></a></div></div>`
  },
  {
    id: 19,
    type: "news",
    title: `Dynamic Partnership Between OBiO Technology and magicRNA to Revolutionize Nucleic Acid Drug Utilization`,
    time: "April 3rd 2024",
    img: handleViteImages("uploads/image/20240404/20240404103641_22819.png"),
    subhead: "",
    content: `Recently, OBiO Technology (Shanghai) Co., Ltd. (hereinafter referred to as " OBiO," stock code: 688238) and Shenzhen magicRNA Technology Co., Ltd. (hereinafter referred to as " magicRNA ") announced the signing of a strategic cooperation agreement. Both sides will carry out comprehensive cooperation in the field of LNP delivery systems...`,
    html: `<div class="Insights-detail-text text">
    <p class="MsoNormal" style="font-size:12pt;font-family:Aptos, sans-serif;text-align:justify;">
Recently, OBiO Technology (Shanghai) Co., Ltd. (hereinafter referred to as " OBiO," stock code: 688238) and Shenzhen magicRNA Technology Co., Ltd. (hereinafter referred to as " magicRNA ") announced the signing of a strategic cooperation agreement. Both sides will carry out comprehensive cooperation in the field of LNP delivery systems, jointly promoting the clinical application of mRNA and other nucleic acid products in the fields of vaccines and cancer therapy. They aim to provide comprehensive and high-quality services to customers, enabling the industry and benefiting patients.
</p>
<p class="MsoNormal" style="font-size:12pt;font-family:Aptos, sans-serif;text-align:justify;">
&nbsp;
</p>
<p class="MsoNormal" style="font-size:12pt;font-family:Aptos, sans-serif;text-align:justify;">
Win-win Cooperation: OBiO &amp; magicRNA
</p>
<p class="MsoNormal" style="font-size:12pt;font-family:Aptos, sans-serif;text-align:justify;">
magicRNA focuses on nucleic acid drug delivery and therapeutic mRNA innovative drug research and development. It possesses the largest ionizable amino lipid library with completely independent intellectual property rights in China. It has applied for more than 10 invention patents, including several PCT and European and American invention patents, of which 4 patents have been authorized. Based on combinatorial chemistry, magicRNA has developed a new ionizable amino lipid with 1,2-diester as the core framework, enabling rapid liver clearance. Engineered cell-targeted delivery platforms enable precise cell targeting to safely and efficiently deliver mRNA.
</p>
<p class="MsoNormal" style="font-size:12pt;font-family:Aptos, sans-serif;text-align:justify;">
In the future, OBiO will continue to build on its own process and technological advantages, as well as various new LNP-related patented technologies proprietary by Irwin Biological, to provide customers with mRNA and other nucleic acids, from early research and development to clinical trial applications, and from clinical GMP manufacturing to commercial GMP manufacturing.
</p>
<p class="MsoNormal" style="font-size:12pt;font-family:Aptos, sans-serif;text-align:justify;">
<img src="${handleViteImages("uploads/image/20240404/20240404103641_22819.png")}" alt="">
</p>
<p class="MsoNormal" style="font-size:12pt;font-family:Aptos, sans-serif;text-align:justify;">
&nbsp;
</p>
<p class="MsoNormal" style="font-size:12pt;font-family:Aptos, sans-serif;text-align:justify;">
Dr.Gaofeng,Zha, founder of magicRNA Techonology,, said: “OBiO is a leading CRO and CDMO enterprise in the field of CGT in China. We are very pleased to have reached a strategic cooperation with OBiO, and also thank OBiO for its recognition of Rainbow Biology. We believe that Rainbow Biology's LNP technology can bring more possibilities and better services to OBiO and its customers. We look forward to collaborating with OBiO to advance the nucleic acid industry and further address unmet clinical needs.”
</p>
<p class="MsoNormal" style="font-size:12pt;font-family:Aptos, sans-serif;text-align:justify;">
Dr.Guodong,Jia, CEO of OBiO Techonology, said: “We are very pleased to cooperate with magicRNA in the field of LNP delivery. Both parties will play their respective advantages to provide strong support for customer product development and jointly promote the application and development of mRNA and other nucleic acid drugs. As a leading company in the industry, OBiO has been committed to promoting the innovation and development of gene and cell therapy, and continuously empowering the entire industry through technological innovation and resource integration. We believe that the collaboration between the two parties will promote the development of nucleic acid drugs in clinical practice.”
</p>
<p class="MsoNormal" style="font-size:12pt;font-family:Aptos, sans-serif;text-align:justify;">
<b>About magicRNA Technology</b>
</p>
<p class="MsoNormal" style="font-size:12pt;font-family:Aptos, sans-serif;text-align:justify;">
Founded in December 2021, magicRNA is a research and development company focused on nucleic acid drug delivery and therapeutic mRNA innovation. Its corporate mission is "Deepening nucleic acid drug delivery, RNA therapy for the benefit of sufferers." HN2201, magicRNA 's first cancer therapy drug, has completed pre-clinical development and obtained ethical clinical trial approval. It is about to enter the clinical trial stage. ILB3132, which is screened from magicRNA lipid library, has completed the development of CMC, is about to complete the registration of Sino-US excipients, and has been authorized for use in several foreign countries, with a cooperation amount of hundreds of millions of yuan. At the same time, in response to industry pain points, Rainbow Bio has successfully developed an engineered cell-targeted delivery platform (Engineered Cell Targeted LNPs, EnC-LNPs). The platform enables engineered and precise cell-targeted delivery and has comparable physicochemical properties and stability to traditional LNPs. They have achieved nearly 100% efficient and selective delivery of immune cells in vitro and in vivo and have completed a patented layout, promising to deliver targeted cells to any purpose in the future.
</p>
<p class="MsoNormal" style="font-size:12pt;font-family:Aptos, sans-serif;text-align:justify;">
<img src="${handleViteImages("uploads/image/20240404/20240404103707_16411.png")}" alt="">
</p>
<p class="MsoNormal" style="font-size:12pt;font-family:Aptos, sans-serif;text-align:justify;">
<b>About OBiO Technology</b>
</p>
<p class="MsoNormal" style="font-size:12pt;font-family:Aptos, sans-serif;text-align:justify;">
The state-of-the-art 77,000 ㎡ (828,821 ft²) Facility for Global Supply exemplifies our commitment to meeting worldwide demand. We provide comprehensive CDMO services encompassing process development, analytical methods, IND-enabling CMC (Chemistry, Manufacturing, and Controls), as well as clinical and commercial manufacturing for viral vector, oncolytic virus, and cell therapy products. Our expertise extends to offering holistic solutions tailored to support the industrialization and commercialization of various products at the Pre-IND stage and beyond.
</p>
<p class="MsoNormal" style="font-size:12pt;font-family:Aptos, sans-serif;text-align:justify;">
<img src="${handleViteImages("uploads/image/20240404/20240404103726_79526.png")}" alt="">
</p>                </div>`,
  },
  {
    id: 18,
    type: "news",
    title: `The 2024 Cell and Gene Therapy Workshop, "Horizons Unveiled: Exploring the Future of Cell and Gene Therapy," concluded successfully this past Saturday`,
    time: "April 3rd 2024",
    subhead: "",
    content: `OBiO Tech want to extend our heartfelt thanks to all the speakers for delivering insightful presentations and sharing the latest topics and solutions. With over 100 attendees, we appreciate the passion and professionalism demonstrated through your engaging questions. We hope you all found the workshop enriching and enjoyable.`,
    html: `<div class="Insights-detail-text text">
    OBiO Tech want to extend our heartfelt thanks to all the speakers for delivering insightful presentations and sharing the latest topics and solutions. With over 100 attendees, we appreciate the passion and professionalism demonstrated through your engaging questions. We hope you all found the workshop enriching and enjoyable.<br>
<p>
<br>
</p>
<p>
<img src="${handleViteImages("uploads/image/20240404/20240404103020_79778.jpg")}" alt=""> 
</p>
<p>
<br>
</p>
<p>
<img src="${handleViteImages("uploads/image/20240404/20240404103032_21644.jpg")}" alt=""> 
</p>
<p>
<br>
</p>
<p>
It was an honor and pleasure for OBiO Tech to be part of such a well-executed and impactful event. As a sponsor, we were thoroughly impressed by the professionalism and efficiency displayed by the Sino-American Pharmaceutical Professionals Association–New England/Boston (SAPA-NE) team throughout the entire process, especially Dr. Peng Sun, Bo YanBo Yan, Tracy ZhangTracy Zhang . We also want to extend our gratitude to Biocytogen for their unconditionally support, especially Madeline LeeMadeline Lee Yin HuangYin Huang Collaborating with such a talented and dedicated group of individuals was truly delightful.
</p>
<p>
<br>
</p>
<p>
Furthermore, we commend the event's impact as not only a fantastic platform for networking and knowledge-sharing but also for successfully achieving its objectives and making a positive difference in our industry and community.
</p>
<p>
<br>
</p>
<p>
<img src="${handleViteImages("uploads/image/20240404/20240404103125_21481.jpg")}" alt=""> 
</p>
<p>
<br>
</p>
<p>
<img src="${handleViteImages("uploads/image/20240404/20240404103137_52796.jpg")}" alt=""> 
</p>
<br>
We encourage you to share this event for future opportunities. We have two more workshops scheduled later this year, and we look forward to your continued participation.<br>
<br>
<p>
Thank you once again for your support and contribution to the success of the workshop.
</p>
<p>
<br>
</p>
<p>
<img src="${handleViteImages("uploads/image/20240404/20240404103240_76460.jpg")}" alt=""> 
</p>
<p>
<br>
</p>
<p>
<img src="${handleViteImages("uploads/image/20240404/20240404103253_40004.jpg")}" alt=""> 
</p>
<br>
The 2024 Cell and Gene Therapy Workshop, "Horizons Unveiled: Exploring the Future of Cell and Gene Therapy," concluded successfully this past Saturday.&nbsp;<br>
<br>
<p>
OBiO Tech want to extend our heartfelt thanks to all the speakers for delivering insightful presentations and sharing the latest topics and solutions.&nbsp;
</p>
<p>
<br>
</p>
<p>
<img src="${handleViteImages("uploads/image/20240404/20240404103339_61826.jpg")}" alt="">
</p>
<p>
<br>
</p>
<p>
<img src="${handleViteImages("uploads/image/20240404/20240404103355_98973.jpg")}" alt="">
</p>                </div>`,
  },
  {
    id: 17,
    type: "news",
    title: `Breaking News: OBiO Technology and Novabio Therapeutics Join Forces in Revolutionary Treg Cell Therapy Partnership!`,
    time: "March 25th 2024",
    img: handleViteImages("uploads/image/20240326/20240326104925_47289.png"),
    subhead:
      "This partnership addressed critical gaps in the treatment of neurodegenerative diseases, autoimmune diseases, and metabolic disorders.",
    content: `We are thrilled to announce a groundbreaking collaboration between OBiO Technology (Shanghai) Co., Ltd. ("OBiO Technology", stock code: 688238) and Shanghai Novabio Therapeutics ("Novabio"). On March 22, 2024, both entities formally inked a strategic cooperation agreement that promises to reshape the landscape of Treg cell therapy.`,
    html: `<div class="Insights-detail-text text">
    <p class="MsoNormal" style="font-size:12pt;font-family:Aptos, sans-serif;">
<span style="font-size:12pt;"><br>
</span>
</p>
<p class="MsoNormal" style="font-size:12pt;font-family:Aptos, sans-serif;">
<span style="font-size:12pt;">We are thrilled to announce a groundbreaking collaboration between OBiO Technology (Shanghai) Co., Ltd. ("OBiO Technology", stock code: 688238) and Shanghai Novabio Therapeutics ("Novabio"). On March 22, 2024, both entities formally inked a strategic cooperation agreement that promises to reshape the landscape of Treg cell therapy.</span> 
</p>
<p class="MsoNormal" style="font-size:12pt;font-family:Aptos, sans-serif;">
<br>
</p>
<p class="MsoNormal" style="text-align:center;font-size:12pt;font-family:Aptos, sans-serif;">
<img src="${handleViteImages("uploads/image/20240326/20240326104925_47289.png")}" alt=""> 
</p>
<p class="MsoNormal" style="text-align:center;font-size:12pt;font-family:Aptos, sans-serif;">
<br>
</p>
<p class="MsoNormal" style="font-size:12pt;font-family:Aptos, sans-serif;">
Under this visionary pact, OBiO Technology commits to providing cutting-edge non-registered clinical trial sample preparation and testing services for Novabio's Treg cell therapy pipeline NP001. Moreover, OBiO Technology will extend its expertise to offer IND application CMC services and clinical sample production services for NP001 and NC001 projects. Together, we aspire to deliver tangible benefits to patients, fostering a brighter future for all.
</p>
<p class="MsoNormal" style="font-size:12pt;font-family:Aptos, sans-serif;">
<br>
</p>
<p class="MsoNormal" style="text-align:center;font-size:12pt;font-family:Aptos, sans-serif;">
<img src="${handleViteImages("uploads/image/20240326/20240326104944_22912.png")}" alt=""> 
</p>
<p class="MsoNormal" style="text-align:center;font-size:12pt;font-family:Aptos, sans-serif;">
<br>
</p>
<p class="MsoNormal" style="font-size:12pt;font-family:Aptos, sans-serif;">
Novabio stands at the forefront of Treg cell therapy drug development, addressing critical gaps in the treatment of neurodegenerative diseases, autoimmune diseases, and metabolic disorders. In a mere year and a half since its inception, Novabio has achieved significant milestones, culminating in the successful process development and validation of the NP001 project. With a primary focus on amyotrophic lateral sclerosis (ALS), plans are underway to conduct innovative IIT research in China, aligning with stringent IND application criteria in both China and the United States.
</p>
<p class="MsoNormal" style="font-size:12pt;font-family:Aptos, sans-serif;">
&nbsp;
</p>
<p class="MsoNormal" style="font-size:12pt;font-family:Aptos, sans-serif;">
Meanwhile, OBiO Technology specializes in offering comprehensive CDMO services tailored to gene and cell therapy drug developers. From pre-clinical research to commercial-scale production, OBiO Technology empowers the entire lifecycle of gene and cell therapy drug development. Boasting state-of-the-art facilities, including 15 vector production lines, 20 cell production lines, and integrated lyophilization and filling capabilities, OBiO Technology epitomizes innovation and excellence in the industry. Our commitment to quality extends to advanced experimental equipment, diverse analysis technologies, and robust detection platforms, ensuring the delivery of high-quality products and services to our valued clientele.
</p>
<p class="MsoNormal" style="font-size:12pt;font-family:Aptos, sans-serif;">
&nbsp;
</p>
<p class="MsoNormal" style="font-size:12pt;font-family:Aptos, sans-serif;">
Ms.Ya, You, General Manager of Novabio, expressed her elation at the strategic collaboration, citing OBiO Technology's unwavering support in various aspects, including cost management, technological expertise, and scheduling precision. Looking ahead, Novabio envisions an era of expanded collaboration, both domestically and internationally, underpinned by mutual trust, support, and empowerment.
</p>
<p class="MsoNormal" style="font-size:12pt;font-family:Aptos, sans-serif;">
&nbsp;
</p>
<p class="MsoNormal" style="font-size:12pt;font-family:Aptos, sans-serif;">
Mr. Javier Jia, CEO and General Manager of OBiO Technology, echoed this sentiment, heralding the partnership with Novabio as a pivotal moment in advancing Treg cell therapy to clinical fruition. As a leading CRO/CDMO enterprise, OBiO Technology remains steadfast in its commitment to driving progress in the global gene and cell therapy field, continuously elevating industry standards through efficient and high-quality service offerings.
</p>
<p class="MsoNormal" style="font-size:12pt;font-family:Aptos, sans-serif;">
<br>
</p>
<p class="MsoNormal" style="text-align:center;font-size:12pt;font-family:Aptos, sans-serif;">
<img src="${handleViteImages("uploads/image/20240326/20240326104958_83831.png")}" alt=""> 
</p>
<p class="MsoNormal" style="text-align:center;font-size:12pt;font-family:Aptos, sans-serif;">
<br>
</p>
<h2 style="font-size:12pt;font-family:Aptos, sans-serif;">
About&nbsp; Novabio Therapeutics
</h2>
<p class="MsoNormal" style="font-size:12pt;font-family:Aptos, sans-serif;">
Founded in 2022, Shanghai Novabio Therapeutics pioneers multimodal Treg cell therapy for treating neurodegenerative diseases, autoimmune disorders, and metabolic conditions. Anchored by a mission to address unmet clinical needs, &nbsp;Novabio espouses core values of patient-centricity, integrity, pragmatism, and persistence, spearheading the industrialization of Treg development.
</p>
<p class="MsoNormal" style="font-size:12pt;font-family:Aptos, sans-serif;">
&nbsp;
</p>
<h2 style="font-size:12pt;font-family:Aptos, sans-serif;">
About OBiO Technology
</h2>
<p style="font-size:12pt;font-family:&quot;">
<span style="font-family:Aptos, sans-serif;">Established in 2013, OBiO Technology (stock code: 688238) is a leading biotechnology firm</span><span style="font-family:DengXian;">，</span><span style="font-family:Aptos, sans-serif;">stands at the forefront of gene and cell therapy, serving as a pioneering CRO and CDMO, dedicated to delivering comprehensive solutions. The state-of-the-art 77,000 ㎡ (828,821 ft²) Facility for Global Supply exemplifies our commitment to meeting worldwide demand. We excel in vectorology studies, functional genomics, and the development of processes and analytics, facilitating Investigational New Drug (IND) readiness and the full spectrum of clinical and commercial manufacturing. Guided by our mission to "enable gene therapy for better lives," we prioritize providing top-tier services on a global scale. From laboratory to clinic, we tirelessly advance your products, impacting populations across the globe. Our steadfast dedication ensures the delivery of high-quality CDMO services throughout the preclinical, IND, clinical, and commercial stages. Our offerings include expertise in plasmids, mRNA, AAV, LVV, Ad viral vectors, cell therapy, CAR-T, NK, Treg, oncolytic viruses, and cutting-edge technologies such as inducible viral vector packaging, ultralow endotoxin processes, and AAVneO for tissue-specific AAV variants.</span> 
</p>
<p class="MsoNormal" style="font-size:12pt;font-family:Aptos, sans-serif;">
&nbsp;
</p>                </div>`,
  },
  {
    id: 16,
    type: "news",
    title: `Embark on a Journey to 'Cure the Future' with Dr. Pan, the visionary founder and chairman of OBiO Biotechnology`,
    time: "March 17th 2024",
    subhead: "",
    content: `Join us as we share our daring and relentless entrepreneurial quest, beginning in 2006, dedicated to innovating in the CGT arena.`,
    html: `<div class="Insights-detail-text text">
    <p>
Join us as we share our daring and relentless entrepreneurial quest, beginning in 2006, dedicated to innovating in the CGT arena.
</p>
<p>
<br>
</p>
<iframe width="560" height="315" src="https://www.youtube.com/embed/2T4Dnv6wQ-U?si=osdqzd4X3kIdzOsG" title="YouTube video player" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" allowfullscreen=""></iframe>                </div>`,
  },
  {
    id: 15,
    type: "news",
    title: `We are thrilled to introduce Hung Trinh, who has joined OBiO Tech as our Senior BD Director. Another all-in team player!`,
    time: "March 2nd 2024",
    subhead: "",
    content: `Dr. Trinh brings with him a wealth of expertise, having been trained as a virologist at the University of Zurich, Switzerland. With a remarkable portfolio of over 30 peer-reviewed articles in virology and vaccine development...`,
    html: `<div class="Insights-detail-text text">
    <p>
<span style="font-size:14px;">We are thrilled to introduce Hung Trinh, who has joined OBiO Tech as our Senior BD Director. Another all-in team player!</span> 
</p>
<p>
<span style="font-size:14px;"><br>
</span> 
</p>
<p>
<span style="font-size:14px;"><img src="${handleViteImages("uploads/image/20240303/20240303064431_62705.jpg")}" alt=""><br>
</span> 
</p>
<p>
<span style="font-size:14px;"><br>
</span> 
</p>
<span style="font-size:14px;">Please join us on Linkedin:www.linkedin.com/company/41870372&nbsp;</span><span style="font-size:14px;">to extend a warm welcome to Dr. Trinh as he becomes a valued member of the OBiO Tech family!</span><br>
<br>
<span style="font-size:14px;">Dr. Trinh brings with him a wealth of expertise, having been trained as a virologist at the University of Zurich, Switzerland. With a remarkable portfolio of over 30 peer-reviewed articles in virology and vaccine development, he is poised to make significant contributions to our team.</span><br>
<span style="font-size:14px;">His primary focus lies in developing manufacturing processes aimed at reducing the cost of manufacturing for cell and gene therapy products, ultimately making advanced medicines more accessible to patients.</span><br>                </div>`,
  },
  {
    id: 13,
    type: "news",
    title: `Please join us in welcoming Swati to OBiO Tech`,
    time: "February 16th 2024",
    subhead: "",
    content: `We are excited to announce Swati Dhage joined OBiO Tech as HR Manager   Swati has garnered broad HR expertise across a range of industries over the course of 12 years, including IT, pharmaceutical manufacturing, healthcare, and life sciences.`,
    html: `<div class="Insights-detail-text text">
                   <p style="text-align:justify;">
	<span style="color:rgba(0, 0, 0, 0.9);font-family:&quot;font-size:14px;">We are excited to announce Swati Dhage joined OBiO Tech as HR Manager
&nbsp;
Swati has garnered broad HR expertise across a range of industries over the course of 12 years, including IT, pharmaceutical manufacturing, healthcare, and life sciences. Her experience extends to leading HR system establishment in startup ventures, encompassing the inception phase through ongoing management to foster company growth.
&nbsp;
Please join us in welcoming Swati to OBiO Tech.</span> 
</p>
<p>
	<span style="color:rgba(0, 0, 0, 0.9);font-family:&quot;font-size:16px;"><br>
  </span> 
</p>
<p style="text-align:center;">
	<img src="${handleViteImages("uploads/image/20240216/20240216214227_52749.jpeg")}" alt=""> 
</p>
<p>
	<br>
</p>                </div>`,
  },
  {
    id: 14,
    type: "news",
    title: `Discover the Ultimate One-Step Method to Perfectly Cultivate Prokaryotic Cells ! Revolutionize Your Cell Cultivation Experience!`,
    time: "February 6th 2024",
    subhead: "",
    content: ``,
    html: `<div class="Insights-detail-text text">
                   <p style="text-align:center;">
	<img src="${handleViteImages("uploads/image/20240207/20240207072156_63851.png")}" alt=""> 
</p>
<p style="text-align:center;">
	<span style="font-size:12pt;font-family:Aptos, sans-serif;"><br>
</span>
</p>
<p style="text-align:left;">
	<span style="font-size:12pt;font-family:Aptos, sans-serif;"><span style="font-size:16px;"></span>
	</span></p><p class="p1" style="text-align:justify;font-size:14px;font-family:Times;color:#374151;">
		<span style="font-size:16px;">The global biopharmaceutical market is experiencing steady growth, fueled by advancements in biotechnology, continuous global population expansion, an aging demographic, and numerous unmet medical needs. However, the complexity of bioproducts, especially gene and cell therapy products, presents challenges such as their diverse nature, high sensitivity, lengthy production processes, complex manufacturing requirements, and various raw material types. </span><b><span style="font-size:16px;">These factors underscore the importance of stringent aseptic risk control</span></b><span style="font-size:16px;"> during the production process, making single-use technology a crucial asset in mitigating such risks.</span>
	</p>
	<p class="p1" style="text-align:justify;font-size:14px;font-family:Times;color:#374151;">
		<span style="font-size:16px;"><br>
</span>
	</p>
	<p class="p1" style="text-align:justify;font-size:14px;font-family:Times;color:#374151;">
		<span style="font-size:16px;">At the end of 2022, ReportLinker published a report titled </span><i><span style="font-size:16px;">Global Single-Use Bioprocessing Market</span></i><span style="font-size:16px;">, which underscored the prevailing use of stainless-steel tank </span><span class="s1" style="color:#000000;font-size:16px;">production processes in commercial biopharmaceutical manufacturing. </span><span style="font-size:16px;">due to their economic feasibility. However, concurrent with evolving regulatory requirements, demand for production flexibility, risk reduction in cross-contamination (particularly in smaller-scale commercial stages), enhanced production efficiency, and reduced investment costs, single-use bioprocessing systems have surged in popularity. </span><b><span style="font-size:16px;">They now dominate the pre-commercialization market for biophåarmaceutical production</span></b><span style="font-size:16px;"> and are gradually expanding their footprint in commercial production.</span>
	</p>
	<p class="p2" style="text-align:justify;font-size:14px;font-family:Times;color:#374151;">
		<br>
	</p>
	<p class="p1" style="text-align:justify;font-size:14px;font-family:Times;color:#374151;">
		<b><span style="font-size:16px;">The Benefits of One-Step Disposal </span><span class="Apple-converted-space" style="font-size:16px;">&nbsp;</span></b>
	</p>
	<p class="p1" style="text-align:justify;font-size:14px;font-family:Times;color:#374151;">
		<b><span class="Apple-converted-space" style="font-size:16px;"><br>
</span></b>
	</p>
	<p class="p3" style="font-size:14px;font-family:Times;color:#0D0D0D;">
		<span style="font-size:16px;">The initial iteration of disposable production processes, labeled as Version 1.0, predominantly focused on disposable upstream fermentation techniques. This methodology frequently employed disposable bags for Escherichia coli fermentation, particularly in plasmid production. Nonetheless, the landscape has since evolved significantly. Innovations in both upstream and downstream supply chains, alongside the embrace of the Quality by Design (QbD) framework, have catalyzed the emergence of a novel approach: the one-step disposable process for prokaryotic cell culture, specifically tailored for plasmid production.</span>
	</p>
	<p class="p4" style="font-size:14px;font-family:Times;color:#0D0D0D;">
		<br>
	</p>
	<p class="p5" style="font-size:14px;font-family:Times;color:#374151;">
		<span style="font-size:16px;">This innovative approach </span><b><span style="font-size:16px;">ensures complete aseptic control throughout the entire process,</span></b><span style="font-size:16px;"> with all steps — from inoculation to fermentation, cell harvesting, lysis, clarification filtration, ultrafiltration, and chromatography — conducted in a fully enclosed manner. It addresses the challenges of aseptic control in producing viral vector plasmids, naked plasmids, and bacterial preparations. Moreover, employing disposable consumables eliminates the risk of cross-contamination between different products, obviating the need for residual testing during product changeover. Consequently, this simplifies cleaning process development and alleviates challenges related to regulatory compliance regarding residual testing specificity and sensitivity, maximizing cross-contamination risk mitigation.</span><span class="s1" style="color:#000000;font-size:16px;">&nbsp;</span>
	</p>
<span style="font-size:16px;"></span><span style="font-size:16px;"></span>
<p></p>
<p>
	<br>
</p>
<p style="text-align:center;">
	<img src="${handleViteImages("uploads/image/20240207/20240207072314_59922.png")}" alt=""> 
</p>
<p style="text-align:center;">
	<br>
</p>
<p style="text-align:left;">
	<span style="font-size:16px;"></span>
	</p><p class="p1" style="text-align:justify;font-size:14px;font-family:Times;color:#374151;">
		<b><span style="font-size:16px;">Challenges of the one-step disposable process for prokaryotic cell culture (plasmid) production</span></b>
	</p>
	<p class="p1" style="text-align:justify;font-size:14px;font-family:Times;color:#374151;">
		<b><span style="font-size:16px;"><br>
</span></b>
	</p>
	<p class="p1" style="text-align:justify;font-size:14px;font-family:Times;color:#374151;">
		<span style="font-size:16px;">Despite its advantages, the one-step disposable process presents challenges compared to highly automated stainless-steel systems, particularly in terms of process complexity and manual intervention requirements. Challenges include:</span>
	</p>
	<ul class="ul1" style="font-size:medium;">
		<li class="li1" style="text-align:justify;font-size:14px;font-family:Times;color:#374151;">
			<b><span style="font-size:16px;">Process Complexity:</span></b><span style="font-size:16px;"> The production process involves multiple steps, including inoculation, fermentation, harvesting, lysis, clarification filtration, ultrafiltration, chromatography, etc. Each step requires precise control and optimization to ensure product quality and yield.</span>
		</li>
		<li class="li1" style="text-align:justify;font-size:14px;font-family:Times;color:#374151;">
			<span class="s1" style="color:#000000;font-size:16px;"><b>Control of Cell Culture Conditions:</b></span><span style="font-size:16px;"> Strict control of parameters such as temperature, pH, oxygen content, nutrient concentrations, etc., is crucial for promoting cell growth and expression of the target product during prokaryotic cell culture.</span>
		</li>
		<li class="li1" style="text-align:justify;font-size:14px;font-family:Times;color:#374151;">
			<span class="s1" style="color:#000000;font-size:16px;"><b>Selection and Maintenance of Strains:</b></span><span style="font-size:16px;"> Proper selection of bacterial strains is essential for the success of the production process. Effective preservation and maintenance of strains are also necessary to ensure their stability and viability.</span>
		</li>
		<li class="li1" style="text-align:justify;font-size:14px;font-family:Times;color:#374151;">
			<span class="s1" style="color:#000000;font-size:16px;"><b>Aseptic Control of Production Processes:</b></span><span style="font-size:16px;"> While disposable processes can reduce the risk of cross-contamination, strict aseptic operation control is still required to ensure product purity and safety.</span>
		</li>
		<li class="li1" style="text-align:justify;font-size:14px;font-family:Times;color:#374151;">
			<span class="s1" style="color:#000000;font-size:16px;"><b>Stability of Plasmid Construction and Expression:</b></span><span style="font-size:16px;"> The stability of plasmid construction and expression directly impacts the quality and yield of the final product, requiring careful design and optimization.</span>
		</li>
		<li class="li1" style="text-align:justify;font-size:14px;font-family:Times;color:#374151;">
			<span class="s1" style="color:#000000;font-size:16px;"><b>Product Purification and Refinement:</b></span><span style="font-size:16px;"> Multiple purification and refinement steps, including lysis, clarification filtration, ultrafiltration, chromatography, etc., are necessary during the production process. Each step needs to effectively remove impurities and improve the purity of the target product.</span>
		</li>
	</ul>
<p></p>
<p class="MsoListParagraphCxSpLast" style="font-size:12pt;font-family:Aptos, sans-serif;text-align:justify;text-indent:-0.25in;">
	<br>
</p>
<p style="text-align:center;">
	<img src="${handleViteImages("uploads/image/20240207/20240207072406_35714.png")}" alt=""> 
</p>
<p>
	<br>
</p>
<p class="MsoNormal" style="font-size:12pt;font-family:Aptos, sans-serif;text-align:justify;">
	</p><p class="p1" style="text-align:justify;font-size:14px;font-family:Times;color:#374151;">
		<b><span style="font-size:16px;">Maintaining Quality and Quantity - Comparable Yield to Stainless-Steel Systems</span></b>
	</p>
	<p class="p1" style="text-align:justify;font-size:14px;font-family:Times;color:#374151;">
		<b><span style="font-size:16px;"><br>
</span></b>
	</p>
	<p class="p1" style="text-align:justify;font-size:14px;font-family:Times;color:#374151;">
		<span style="font-size:16px;">With over 20 batches of disposable GMP plasmid production experience, OBiO Tech has demonstrated that the yield of disposable process systems matches that of stainless-steel systems, as shown in Figure 1.</span><span class="Apple-converted-space" style="font-size:16px;">&nbsp;</span><span style="font-family:Aptos, sans-serif;font-size:16px;"></span>
	</p>
<p></p>
<p class="MsoNormal" style="font-size:12pt;font-family:Aptos, sans-serif;text-align:justify;">
	<span style="font-family:&quot;color:#374151;"><br>
         </span> 
</p>
<div style="text-align:center;">
	<img src="${handleViteImages("uploads/image/20240207/20240207072447_17161.png")}" alt=""> 
</div>
<p>
	<br>
</p>
<p>
	<span style="font-size:12pt;line-height:18.4px;font-family:Aptos, sans-serif;"></span><span style="font-size:medium;"></span> 
</p>
<p class="MsoNormal" align="center" style="font-size:12pt;font-family:Aptos, sans-serif;text-align:center;">
	<span style="font-size:16px;line-height:13.8px;font-family:&quot;">Figure 1: Comparison of Plasmid Yield from Escherichia coli Fermentation</span>
</p>
<p class="p1" style="text-align:justify;font-family:Times;color:#374151;">
	<br>
</p>
<p class="p1" style="text-align:justify;font-family:Times;color:#374151;">
	<span style="font-size:18px;">
	</span></p><p class="p1" style="text-align:justify;font-size:14px;font-family:Times;color:#374151;">
		<span style="font-size:16px;">Apart from the performance of cultivation, another important factor affecting production capacity is turnover rate. Due to the faster turnover rate of disposable process systems, the capacity of this platform is double that of stainless-steel fermentation tanks. The one-step disposable process for a prokaryotic cell culture (plasmid) production system can produce 135 batches per year, while stainless-steel systems can produce 67 batches per year.</span>
	</p>
	<p class="p1" style="text-align:justify;font-size:14px;font-family:Times;color:#374151;">
		<span style="font-size:16px;"><br>
</span>
	</p>
	<p class="p1" style="text-align:justify;font-size:14px;font-family:Times;color:#374151;">
		<b><span style="font-size:16px;">A comprehensive and flexible platform for prokaryotic cell culture (plasmid) production</span></b>
	</p>
	<p class="p1" style="text-align:justify;font-size:14px;font-family:Times;color:#374151;">
		<b><span style="font-size:16px;"><br>
</span></b>
	</p>
	<p class="p1" style="text-align:justify;font-size:14px;font-family:Times;color:#374151;">
		<span style="font-size:16px;">Located within a sprawling 77,000 ㎡ (828,821 ft²) Lingang Industrial site, OBiO Tech's facility stands as a cornerstone in the precision medical industry. It boasts three distinct production lines tailored for commercial GMP production of prokaryotic cell culture (plasmid), including: a cutting-edge, one-step disposable process production line, a versatile 10L-50L-500L bioreactor production line, and a reliable stainless-steel system production line.</span>
	</p>
	<p class="p1" style="text-align:justify;font-size:14px;font-family:Times;color:#374151;">
		<span style="font-size:16px;"><br>
</span>
	</p>
	<p class="p1" style="text-align:justify;font-size:14px;font-family:Times;color:#374151;">
		<span style="font-size:16px;">Guided by the principles of QbD and BSL-2, OBiO Tech's CDMO platform offers rapid, tailored solutions for various plasmid products and bacterial preparations, catering to diverse production requirements. Whether it’s plasmids for viral vector production, naked plasmids, or bacterial preparations, OBiO Tech's platform provides a spectrum of equipment with varying capacities and flexible facility configurations, ensuring adaptability to unique needs.</span>
	</p>
	<p class="p1" style="text-align:justify;font-size:14px;font-family:Times;color:#374151;">
		<span style="font-size:16px;"><br>
</span>
	</p>
	<p class="p1" style="text-align:justify;font-size:14px;font-family:Times;color:#374151;">
		<span style="font-size:16px;">Distinguished by its meticulous design, the platform delineates between areas for live organisms and non-live organisms, with meticulously planned flows for personnel, materials, and waste. This segregation not only enhances biosafety but also accelerates product transformation speed, exemplifying our commitment to efficiency and excellence in biopharmaceutical production.</span>
	</p>

<p></p>
<p class="p1" style="text-align:justify;font-family:Times;color:#374151;">
	<span style="font-size:18px;"></span> 
</p>
<p>
	<br>
</p>
<p>
	<br>
</p>
<div style="text-align:center;">
	<img src="${handleViteImages("uploads/image/20240207/20240207072529_99814.png")}" alt=""> 
</div>
<p>
	<br>
</p>                </div>`,
  },
  {
    id: 1,
    type: "news",
    title: `Focusing on efficient gene delivery of NK cells, The First Condor Life and OBiO Technology reach a strategic cooperation!`,
    time: "January 13th 2024",
    subhead: "",
    content: `The First Condor Life and OBiO Technology have reached a strategic cooperation. In this collaboration, The First Condor Life and OBiO Technology will share resources, complement each other's advantages, jointly address market changes and competitive pressures, and achieve win-win cooperation and sustainable development.
    On December 27th, Shenzhen First Condor Life Science Co. Ltd. (hereinafter referred to as " First Condor Life") in Shenzhen and OBiO Biotechnology (Shanghai) Co., Ltd. (stock code: 688238) (hereinafter referred to as " OBiO Biotech") signed a strategic cooperation agreement in Lingang, Shanghai. First Condor Life's co-founder and CTO, Maria Ma, Quality Director Liu Dong, Early R&D Director Wang Zhongsheng, CAR-NK Platform Head Huang Jing, OBiO Biotech CEO Jia Guodong, Deputy General Manager Yin Shan, and Marketing Director Wang Yao attended the signing ceremony."`,
    html: `<div class="Insights-detail-text text">
    <p
      class="MsoNormal"
      style="
        font-size: 11pt;
        font-family: Calibri, sans-serif;
        text-align: justify;
      "
    >
      <span style='font-size:13.5pt;line-height:19.26px;font-family:"'> </span>
    </p>
    <p
      class="MsoNormal"
      style='font-size:12pt;font-family:"text-align:justify;'
    >
      <span style="font-family: Tahoma, sans-serif"
        >The First Condor Life and OBiO Technology have reached a strategic
        cooperation. In this collaboration, The First Condor Life and OBiO
        Technology will share resources, complement each other's advantages,
        jointly address market changes and competitive pressures, and achieve
        win-win cooperation and sustainable development.</span
      >
    </p>
    <p
      class="MsoNormal"
      style='font-size:12pt;font-family:"text-align:justify;'
    >
      <span style="font-family: Tahoma, sans-serif"><br /> </span>
    </p>
    <span style="font-size: 12pt; font-family: Tahoma, sans-serif"
      >On December 27th, Shenzhen First Condor Life Science Co. Ltd.
      (hereinafter referred to as " First Condor Life") in Shenzhen and OBiO
      Biotechnology (Shanghai) Co., Ltd. (stock code: 688238) (hereinafter
      referred to as " OBiO Biotech") signed a strategic cooperation agreement
      in Lingang, Shanghai. First Condor Life's co-founder and CTO, Maria Ma,
      Quality Director Liu Dong, Early R&amp;D Director Wang Zhongsheng, CAR-NK
      Platform Head Huang Jing, OBiO Biotech CEO Jia Guodong, Deputy General
      Manager Yin Shan, and Marketing Director Wang Yao attended the signing
      ceremony."</span
    ><span style="font-size: medium"></span>
    <p>
      <br />
    </p>
    <p
      class="MsoNormal"
      style="
        font-size: 11pt;
        font-family: Calibri, sans-serif;
        text-align: justify;
      "
    >
      <span style='font-size:13.5pt;line-height:19.26px;font-family:"'
        ><span style="font-size: 12pt; font-family: Tahoma, sans-serif"
          ><br /> </span
      ></span>
    </p>
    <p
      class="MsoNormal"
      style="
        font-size: 11pt;
        font-family: Calibri, sans-serif;
        text-align: justify;
      "
    >
      <span style='font-size:13.5pt;line-height:19.26px;font-family:"'></span>
    </p>
    <p
      class="MsoNormal"
      align="center"
      style="
        font-size: 11pt;
        font-family: Calibri, sans-serif;
        text-align: center;
      "
    >
      <img
        src="${handleViteImages("uploads/image/20240114/20240114104316_42738.png")}"
        alt=""
      />
    </p>
    <p
      class="MsoNormal"
      style="
        font-size: 11pt;
        font-family: Calibri, sans-serif;
        text-align: justify;
      "
    >
      <span style="font-size: 11pt">&nbsp;</span>
    </p>
    <p
      class="MsoNormal"
      style="
        font-size: 11pt;
        font-family: Calibri, sans-serif;
        text-align: justify;
      "
    >
      <span style='font-size:13.5pt;line-height:19.26px;font-family:"'> </span>
    </p>
    <p
      class="MsoNormal"
      style='font-size:12pt;font-family:"text-align:justify;'
    >
      <span style="font-family: Tahoma, sans-serif"
        >With the vigorous development of biomedicine, lentiviral vectors, due
        to their characteristics of safety, stable integration and expression,
        and the ability to carry large gene segments, have been widely used as a
        core tool for gene delivery in both basic research and clinical
        treatment. Scientists continue to conduct in-depth research on
        lentiviral vectors, and their many iterations have laid the foundation
        for industry development. CAR-NK therapy is expected to become another
        blockbuster product after CAR-T therapy. The gene delivery of NK cells
        is an extremely important part of the CAR-NK production process and is
        currently a significant industry challenge. Solving the problem of
        efficiently transducing NK cells with lentiviruses can provide strong
        support for the development of CAR-NK therapy.</span
      >
    </p>
    <p
      class="MsoNormal"
      style='font-size:12pt;font-family:"text-align:justify;'
    >
      <span style="font-family: Tahoma, sans-serif"><br /> </span>
    </p>
    <span style="font-size: 12pt; font-family: Tahoma, sans-serif"
      >Both parties will leverage their respective strengths to engage&nbsp;
      in-depth strategic cooperation, focusing on innovative lentiviral gene
      delivery vectors for efficiently infecting NK cells. Areas of cooperation
      include, but are not limited to, the application and commercial promotion
      of innovative vectors in basic research and drug development, optimization
      of the production process for innovative vectors, and enhancements in
      safety, efficacy, and stability. Additionally, the two parties will
      collaborate closely to advance further technical exchanges in cell
      therapy, collectively promoting the cell therapy clinical application for
      the benefit of more patients.</span
    ><span style="font-size: medium"></span>
    <p>
      <br />
    </p>
    <p
      class="MsoNormal"
      style="
        font-size: 11pt;
        font-family: Calibri, sans-serif;
        text-align: justify;
      "
    >
      <span style='font-size:13.5pt;line-height:19.26px;font-family:"'
        ><span style="font-size: 12pt; font-family: Tahoma, sans-serif"
          ><br /> </span
      ></span>
    </p>
    <p
      class="MsoNormal"
      style="
        font-size: 11pt;
        font-family: Calibri, sans-serif;
        text-align: justify;
      "
    >
      <span style='font-size:13.5pt;line-height:19.26px;font-family:"'></span>
    </p>
    <p style="text-align: center">
      <img
        src="${handleViteImages("uploads/image/20240114/20240114104336_15375.png")}"
        alt=""
      />
    </p>
    <p style="text-align: center">
      <br />
    </p>
    <p
      class="MsoNormal"
      style="
        font-size: 11pt;
        font-family: Calibri, sans-serif;
        text-align: justify;
      "
    >
      <span style='font-size:13.5pt;line-height:19.26px;font-family:"'> </span>
    </p>
    <p
      class="MsoNormal"
      style='font-size:12pt;font-family:"text-align:justify;'
    >
      <span style="font-family: Tahoma, sans-serif"
        >First Condor Life's co-founder and CTO, Maria Ma, expressed deep
        gratitude for the trust and support from OBiO Tech. She stated, “We are
        delighted to collaborate with OBiO Tech to explore possibilities in the
        field of life sciences. First Condor Life has been committed to
        developing cell therapies for solid tumors, including CAR-T and CAR-NK.
        In this collaboration we are focusing on lentiviral system specifically
        designed for NK cells. The modified and optimized lentiviral system
        achieved a breakthrough in the efficiency of NK cell infection, which
        will have profound implications for NK cell based research and drug
        development. As a leading CDMO company, OBiO Tech possesses excellent
        technical capabilities and market promotion abilities. Through
        Leveraging the strengths of both parties, we believes that this
        collaboration will not only bring mutual benefits but will also make a
        positive contribution to the entire industry and society”</span
      >
    </p>
    <p
      class="MsoNormal"
      style='font-size:12pt;font-family:"text-align:justify;'
    >
      <span style="font-family: Tahoma, sans-serif"><br /> </span>
    </p>
    <p
      class="MsoNormal"
      style='font-size:12pt;font-family:"text-align:justify;'
    >
      <span style="font-family: Tahoma, sans-serif"
        >CEO of OBiO Biotech, Guodong Jia, expressed his pleasure in
        establishing a strategic cooperation with First Condor Life, emphasizing
        that OBiO Tech has consistently focused on the fields of gene and cell
        therapy, with the mission of "enable gene therapy for better lives”. The
        company specializes in the research and development of viral vectors and
        large-scale manufacturing. as its two core technology clusters and
        continuously commits to addressing challenges to meet the unmet needs of
        customers and patients. Since its establishment, the company has
        consistently pursued technological innovation, balancing between
        independent research and development and external collaboration in order
        to make innovative breakthroughs to empower industry development.
        Looking ahead, OBiO Biotech expects that the lentiviral system for NK
        cells developed in this collaboration can be utilized by more
        researchers or pharmaceutical companies, maximizing its value.</span
      >
    </p>
    <p
      class="MsoNormal"
      style='font-size:12pt;font-family:"text-align:justify;'
    >
      <span style="font-family: Tahoma, sans-serif"><br /> </span>
    </p>
    <p
      class="MsoNormal"
      style='font-size:12pt;font-family:"text-align:justify;'
    >
      <span style="font-family: Tahoma, sans-serif"
        >He expressed the hope for sincere cooperation between the two parties,
        anticipating that more collaboration in the future.</span
      >
    </p>
    <p
      class="MsoNormal"
      style='font-size:12pt;font-family:"text-align:justify;'
    >
      <span style="font-family: Tahoma, sans-serif"><br /> </span>
    </p>
    <p
      class="MsoNormal"
      style='font-size:12pt;font-family:"text-align:justify;'
    >
      <span style="font-size: 12pt; font-family: Tahoma, sans-serif"> </span>
    </p>
    <p
      class="MsoNormal"
      style='font-size:12pt;font-family:"text-align:justify;'
    >
      <span style="font-family: Tahoma, sans-serif"
        ><strong>About OBiO Technology</strong></span
      >
    </p>
    <br />
    <p>
      <br />
    </p>
    <p
      class="MsoNormal"
      style='font-size:12pt;font-family:"text-align:justify;'
    >
      <span style="font-size: 12pt; font-family: Tahoma, sans-serif"
        >OBiO Technology (Shanghai) Corp., Ltd. (OBiO,
        SSE:688238.SH)&nbsp;</span
      ><span style="font-size: 12pt; font-family: Tahoma, sans-serif"
        >was established in 2013. It is a biotechnology company focusing in the
        field of gene and cell therapy, providing CRO and CDMO services such as
        viral&nbsp; vector development and gene function study for basic
        research as well as CMC development and GMP manufacture of&nbsp;
        plasmids, viral vectors, oncolytic viruses, CAR-T cell therapy products,
        With "enable gene therapy for better lives" as our mission, we are
        committed to providing high-quality service to global customers,
        advancing product from bench to clinic, and bringing benefit to patients
        around the world. For more information about OBiO, visit&nbsp;</span
      ><a href="http://www.obio-tech.com/" target="_blank"
        ><span style="color: black">www.obio-tech.com</span></a
      ><span style="font-size: 12pt; font-family: Tahoma, sans-serif">.</span>
    </p>
    <p
      class="MsoNormal"
      style='font-size:12pt;font-family:"text-align:justify;'
    >
      <br />
    </p>
    <div style="text-align: center">
      <img
       src="${handleViteImages("uploads/image/20240114/20240114104414_98575.png")}"
        alt=""
      />
    </div>
    <p
      class="MsoNormal"
      style="
        font-size: 11pt;
        font-family: Calibri, sans-serif;
        text-align: justify;
      "
    >
      <b
        ><span
          style='font-size:14pt;line-height:19.9733px;font-family:"color:#1F4E79;'
          >&nbsp;</span
        ></b
      >
    </p>
    <p
      class="MsoNormal"
      style="
        font-size: 11pt;
        font-family: Calibri, sans-serif;
        text-align: justify;
      "
    >
      <b
        ><span
          style='font-size:14pt;line-height:19.9733px;font-family:"color:#1F4E79;'
        >
        </span
      ></b>
    </p>
    <p
      class="MsoNormal"
      style='font-size:12pt;font-family:"text-align:justify;'
    >
      <b
        ><span style="font-family: Tahoma, sans-serif"
          >About First Condor Life</span
        >
      </b>
    </p>
    <p
      class="MsoNormal"
      style="
        font-size: 11pt;
        font-family: Calibri, sans-serif;
        text-align: justify;
      "
    >
      <b
        ><b
          ><span
            style='font-size:14pt;line-height:19.9733px;font-family:"color:#1F4E79;'
          ></span
        ></b>
      </b>
    </p>
    <p>
      <br />
    </p>
    <p
      class="MsoNormal"
      style='font-size:12pt;font-family:"text-align:justify;'
    >
      <br />
    </p>
    <p
      class="MsoNormal"
      style='font-size:12pt;font-family:"text-align:justify;'
    >
      <span style="font-family: Tahoma, sans-serif"
        >First Condor Life Science Co., Ltd. was established in March 2020 in
        Shenzhen, with its research and production base located in the Songshan
        Lake High-tech Zone in Dongguan. It is a national high-tech enterprise
        dedicated to the research and industrialization of solid tumor cell
        immunotherapy. The company, guided by independent research and
        development of CAR-T products, simultaneously explores international
        cutting-edge technologies such as CAR-NK and CAR-T. &nbsp;First Condor
        Life has developed three technology platforms with independent
        intellectual property rights: Trans-CAR, Boost-CAR, and R-Star. Clinical
        studies on solid tumor CAR-T targeting CLDN18.2, GCC, and Nectin-4 are
        currently underway in multiple hospitals.</span
      >
    </p>
    <p
      class="MsoNormal"
      style='font-size:12pt;font-family:"text-align:justify;'
    >
      <span style="font-family: Tahoma, sans-serif"><br /> </span>
    </p>
    <p>
      <br />
    </p>
    <p
      class="MsoNormal"
      align="center"
      style="
        font-size: 11pt;
        font-family: Calibri, sans-serif;
        text-align: center;
      "
    >
      <img
        src="${handleViteImages("uploads/image/20240114/20240114104435_61351.png")}"
        alt=""
      />
    </p>
    <p
      class="MsoNormal"
      style="
        font-size: 11pt;
        font-family: Calibri, sans-serif;
        text-align: justify;
      "
    >
      &nbsp;
    </p>
  </div>`,
  },
  {
    id: 2,
    type: "news",
    title: `OBiO Announces Strategic Partnership with Refreshgene to Realize
    Commercialization of Gene Therapy Product`,
    time: "24th Oct. 2023",
    subhead: "Visit OBiO at ESGCT 30th Annual Congress in Brussels",
    content: `OBiO Technology (Shanghai) Corp., Ltd. (OBiO, 688238.SH), a world leading contract development and manufacturing organization for cell and gene therapy, officially announced an agreement with Refreshgene Therapeutics (Refreshgene). Under the agreement, OBiO leverages its capabilities of process development, large-scale cGMP commercial production and global business development to provide high-quality CDMO/CMO services and authorized cooperation services for Refreshgene's RRG-001 pipeline, and jointly promote the development of advanced therapies to benefit patients around the world.`,
    html: `<div class="Insights-detail-text text">
                   <p style="text-align:justify;">
	<span style="line-height:1.5;font-size:16px;">&nbsp; &nbsp; </span><span style="line-height:1.5;font-size:16px;">OBiO Technology (Shanghai) Corp., Ltd.
(OBiO, 688238.SH), a world leading contract development and manufacturing
organization for cell and gene therapy, officially announced an agreement with
Refreshgene Therapeutics (Refreshgene). Under the agreement, OBiO leverages its
capabilities of process development, large-scale cGMP commercial production and
global business development to provide high-quality CDMO/CMO services and
authorized cooperation services for Refreshgene's RRG-001 pipeline, and jointly
promote the development of advanced therapies to benefit patients around the
world.</span> 
</p>
<p class="MsoNormal" style="text-align:justify;margin-left:0cm;">
	<br>
</p>
<p class="MsoNormal" style="text-align:center;margin-left:0cm;">
	<span style="font-size:16px;"></span><img src="${handleViteImages("uploads/image/20231025/20231025110251_39104.jpg")}" alt=""> 
</p>
<p class="MsoNormal" style="text-align:justify;margin-left:0cm;">
	<br>
</p>
<p class="MsoNormal" style="text-align:justify;margin-left:0cm;">
	<span style="line-height:1.5;font-size:16px;">&nbsp;&nbsp;&nbsp;&nbsp;Driven by human
genetics and translational medicine, Refreshgene develops new gene therapy and
drugs to satisfy unmet clinical needs via highly druggable and tissue-specific
gene delivery technology. Refreshgene owns well-established research and
technology system of AAV gene therapy and built up clinic-stage pipeline in the
field of retinal diseases and congenital deafness. Moreover, Refreshgene is the
first gene therapy company in the world to apply dual AAV vector technology
into clinical trials in congenital deafness. And this time, OBiO and
Refreshgene intend to establish a comprehensive strategic partnership for
clinical application, clinical &amp; commercial production and global
commercial cooperation of RRG-001 gene therapy product.</span> 
</p>
<p class="MsoNormal" style="text-align:justify;margin-left:0cm;">
	<br>
</p>
<p class="MsoNormal" style="text-align:justify;margin-left:0cm;">
	<span style="line-height:1.5;font-size:16px;">&nbsp;&nbsp;&nbsp;&nbsp;OBiO focuses on
one-stop CRO/CDMO services from preclinical research, CMC, and clinical
manufacturing to commercial large-scale manufacturing for drug developers in
the field of gene and cell therapy. Currently, OBiO possesses 15 vector
production lines and 20 cell production lines, which can meet GMP production
requirements of different scales. It has laid out a variety of innovative
process systems, including production lines with single-use technology, filling
lines integrated with lyophilizers, and cell therapy production lines for
positive sample. OBiO is at the forefront of the industry.</span> 
</p>
<p class="MsoNormal" style="text-align:justify;margin-left:0cm;">
	<br>
</p>
<p class="MsoNormal" style="text-align:justify;margin-left:0cm;">
	<span style="line-height:1.5;font-size:16px;">&nbsp;&nbsp;&nbsp;&nbsp;Dr. Liu Xinxing,
CEO of Refreshgene said: "In the CMC development of RRG001 pipeline's IND
enabling, we chose to cooperate with OBiO, which is proved to be an experienced
and collaborative CDMO. As a result, we further strengthen and expand the scope
of strategic cooperation with OBiO. We look forward to efficiently bringing
this drug to market and meeting the unmet medical needs on the behave of
patients' benefit."</span> 
</p>
<p class="MsoNormal" style="text-align:justify;margin-left:0cm;">
	<br>
</p>
<p class="MsoNormal" style="text-align:justify;margin-left:0cm;">
	<span style="line-height:1.5;font-size:16px;">&nbsp;&nbsp;&nbsp;&nbsp;Dr. Jia Guodong,
CEO of OBiO, expressed his enthusiasm for the strategic collaboration:
"This cooperation is an important milestone for both parties to promote
the clinical application and the launch of gene therapy drugs. As a
leading&nbsp;CRO/CDMO focusing on the field of gene and cell therapy, we always
pay active attention to the innovative progress in the global gene and cell
therapy, and the demand for large-scale GMP manufacturing, continuously
providing efficient and high-quality services."</span> 
</p>
<p class="MsoNormal" style="text-align:justify;margin-left:0cm;">
	<span style="font-size:16px;">
	</span></p><hr>
	
<p></p>
<p class="MsoNormal" style="text-align:justify;margin-left:0cm;">
	<span style="line-height:1.5;font-size:16px;">&nbsp; &nbsp; Join us at
European Society of Gene and Cell Therapy's 30th Annual Congress
in&nbsp;Brussels,&nbsp;October 24-27.&nbsp;OBiO will be waiting
for&nbsp;everyone&nbsp;at booth #58.&nbsp;Don't miss this opportunity to
connect with&nbsp;OBiO, learn about our cutting-edge technologies, and explore
how OBiO is contributing to the transformation of novel therapeutics.</span> 
</p>
<p class="MsoNormal" style="text-align:justify;margin-left:0cm;">
	<br>
</p>
<p class="MsoNormal" style="text-align:justify;">
	<span style="line-height:1.5;font-size:16px;">Don't miss OBiO's poster:&nbsp;</span> 
</p>
<p class="MsoNormal" style="text-align:justify;">
	<span style="line-height:1.5;font-size:16px;">P171: Overcome the Unpackable GOI in Vector
Manufacturing by Applying the CuO Inducible System</span> 
</p>
<p class="MsoNormal" style="text-align:justify;">
	<span style="line-height:1.5;font-size:16px;">We are preparing surprises at our booth.</span> 
</p>
<p class="MsoNormal" style="text-align:justify;margin-left:0cm;">
	<br>
</p>
<p class="MsoNormal" style="text-align:justify;margin-left:0cm;">
	<span style="line-height:1.5;font-size:16px;"><strong>About Refreshgene</strong></span> 
</p>
<p class="MsoNormal" style="text-align:justify;margin-left:0cm;">
	<span style="line-height:1.5;font-size:16px;">&nbsp;&nbsp;&nbsp;&nbsp;Refreshgene therapeutics is an enterprise
engaged in the research and development of innovative gene therapy. It utilizes
AAV vectors and non-viral vectors to provide precise solutions for the clinical
challenges in the diseases of ophthalmology, otology, cardiovascular and other
rare diseases and chronic diseases, focusing on the development of effective
gene therapy products that are affordable to patients.</span> 
</p>
<p class="MsoNormal" style="text-align:justify;margin-left:0cm;">
	<br>
</p>
<p class="MsoNormal" style="text-align:justify;margin-left:0cm;">
	<span style="line-height:1.5;font-size:16px;"><strong>About OBiO</strong></span> 
</p>
<p class="MsoNormal" style="text-align:justify;margin-left:0cm;">
	<span style="line-height:1.5;font-size:16px;">&nbsp;&nbsp;&nbsp;&nbsp;OBiO&nbsp;Technology is committed&nbsp;to
becoming a global leader in gene and cell therapy CRO and CDMO to serve our
customers worldwide with the best possible. We provide holistic research,
development, manufacturing solutions, functional genomics, process and analytical
development,&nbsp;IND-enabling&nbsp;CMC, clinical and commercial manufacturing
expertise, capabilities, and compliance. Our missing is to "Enable gene
therapy for a better life" through quality service to help advance
advanced therapeutic products to clinics and manufacturing.we are committed to
providing highquality service to global customers, advancing your product from
bench to clinic, and bringing benefit to populations around the world. For more
information about OBiO Technology, visit&nbsp;</span><a href="/" target="_blank"><span style="line-height:1.5;font-size:16px;">www.obio-tech.com</span></a><span style="line-height:1.5;font-size:16px;">.</span> 
</p>
<p style="color:#333333;font-family:Montserrat, &quot;font-size:16px;background-color:#FFFFFF;">
	<span id="spanHghlta1fc"><a href="mailto:bd@obiosh.com" target="_blank"></a></span> 
</p>                </div>`,
  },
  {
    id: 3,
    type: "news",
    title: `OBiO Announces Strategic Partnership with Tofflon to Advance Cell and Gene Therapy Development`,
    time: "31st Aug. ,2023",
    subhead: "",
    content: `OBiO Technology (Shanghai) Corp., Ltd. (”OBiO” or the “Company”, Stock code: SH688238) today announced that it entered into a strategic cooperation agreement (the "Agreement") with today announced that it entered into a strategic cooperation agreement with Shanghai Tofflon Science and Technology Co.Ltd.(Short for “Tofflon”, Stock code: SZ300171).`,
    html: `<div class="Insights-detail-text text">
                   <p style="text-align:justify;">
	<span style="font-size:16px;">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="font-size:16px;">OBiO Technology
(Shanghai) Corp., Ltd. (”OBiO” or the “Company”, Stock code: SH688238) today
announced that it entered into a strategic cooperation agreement (the
"Agreement") with today announced that it entered into a strategic
cooperation agreement with Shanghai Tofflon Science and Technology
Co.Ltd.(Short for “Tofflon”, Stock code: SZ300171).</span> 
</p>
<p style="text-align:justify;">
	<br>
</p>
<p style="text-align:center;">
	<img src="data:image/png;base64,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" alt=""> 
</p>
<p style="text-align:justify;">
	<br>
</p>
<p style="text-align:justify;">
	<span style="font-size:16px;">&nbsp;&nbsp;&nbsp;&nbsp;According to the
agreement, OBiO and Tofflon will cooperate with each other in the field of Cell
and Gene Therapy，OBiO With advanced production processes, quality control
technologies, manufacturing capabilities, and the ability for large-scale
industrialization。And Tofflon provides customized equipment and
manufactured consumable materials. Each party will rely on the resources of the
other party to empower each other and partnering to serve valued customers，in order to improve their competitive
positions. </span> 
</p>
<p style="text-align:justify;">
	<br>
</p>
<p style="text-align:justify;">
	<span style="font-size:16px;">&nbsp;&nbsp;&nbsp;&nbsp;Guodong Jia，CEO of OBiO，said: “Tofflon's produced equipment and
consumable materials are known for their reliability, and their values align
closely with ours. The signing of this strategic agreement accelerates cell and
gene industrial deployment, this strategic agreement aims to facilitate the
better and faster development of the global field of cell and gene therapy.” </span> 
</p>
<p style="text-align:justify;">
	<br>
</p>
<p style="text-align:justify;">
	<span style="font-size:16px;">&nbsp;&nbsp;&nbsp;&nbsp;Xiaodong, Zheng,
CEO of Tofflon stated, "OBiO Technology is a leading CRO and CDMO company
of cell and gene therapy. We are highly honored to strategically cooperate with
OBiO.&nbsp;In future, we will continue to work closely with our own abilities,
to promote the development of the industry.” </span> 
</p>
<p style="text-align:justify;">
	<br>
</p>
<p style="text-align:justify;">
	 <strong><span style="font-size:16px;">About Shanghai
Tofflon Science and Technology Co.Ltd.</span></strong> 
</p>
<p style="text-align:justify;">
	<span style="font-size:16px;">&nbsp;&nbsp;&nbsp;&nbsp;Shanghai Tofflon
Science and Technology Co. Ltd. (Short for "Tofflon", Stock Code: SZ
300171) was founded in 1993. It is a comprehensive pharmaceutical equipment
supplier to provide process support, core equipments, integrated system and
pharma engineering for the pharma and biotech industry in the world. Since its
foundation, Tofflon has supplied more than 8000 equipments and systems for 2000
pharmaceutical companies across over 40 countries and regions in the world
which have been widely applied in the fields of liquid and lyo injectables,
chemical API, bioengineering and pharma packaging, etc. </span> 
</p>
<p style="text-align:justify;">
	<br>
</p>
<p style="text-align:justify;">
	 <strong><span style="font-size:16px;">About OBiO
Technology</span></strong> 
</p>
<p style="text-align:justify;">
	<span style="font-size:16px;">&nbsp;&nbsp;&nbsp;&nbsp;OBiO Technology
(Shanghai) Corp., Ltd. (OBiO, 688238.SH) is a gene and cell therapy-focused CRO
and CDMO founded in 2013. For global customers, we offer holistic
research, development, and manufacturing solutions for vectorology studies,
functional genomics, process and analytical development, IND-enabling CMC,
clinical and commercial manufacturing. With "enable gene therapy for
better lives" as our mission, we are committed to providing high-quality
service to global customers, advancing your product from bench to clinic, and
bringing benefit to populations around the world. For more information about
OBiO Technology, visit <a href="/" target="_blank">www.obio-tech.com</a>.</span> 
</p>                </div>`,
  },
  {
    id: 4,
    type: "news",
    title: `FDA Acceptance of Drug Master File Marks New Milestone Achieved for OBiO TECH of GMP Plasmid Products`,
    time: "29th Jun. ,2023",
    subhead: "",
    content: ``,
    html: `<div class="Insights-detail-text text">
                   <p style="text-align:justify;">
	<span style="font-size:16px;"><span style="font-size:16px;">&nbsp; &nbsp; </span>OBiO Technology (Shanghai) Corp., Ltd
('OBiO', 688238. SH) is a biotechnology company focusing on the cell and gene
therapy field. Recently announced that the U.S. Food and Drug Administration
(FDA) has successfully obtained the GMP plasmid DNA Drug Master File (DMF)
filing, DMF Number 038404 and 038405, together with the previously filed DMF
037766, covering three helper plasmid products required for lentivirus
production.</span>
</p>
<p style="text-align:justify;">
	<span style="font-size:16px;"><br>
</span>
</p>
<p style="text-align:justify;">
	<span style="font-size:16px;"><span style="font-size:16px;">&nbsp; &nbsp; </span>OBiO has completed the DMF filing for the
three helper plasmids used in lentivirus production. The DMF acceptance enables
a direct reference for investigational new drug (IND) filing for lentiviral
vectors, autologous cell therapy,&nbsp;
allogeneic cell therapy, and stem cell therapy products, and drug
developers could be authorized to reference all or part of the content of a DMF
in support of its IND application, This successful filing will further drive
OBiO to provide convenience to more biopharmaceutical companies, saving time
and communication costs for the application filing process and accelerate the
process of drug project submission and approval.</span>
</p>
<p style="text-align:justify;">
	<br>
</p>
<p style="text-align:justify;">
	<img src="${handleViteImages("uploads/image/20230629/20230629093402_63739.jpg")}" alt=""> 
</p>
<p style="text-align:justify;">
	<br>
</p>
<p style="text-align:justify;">
	<span style="font-size:16px;">&nbsp; &nbsp; OBiO offers comprehensive CDMO
solutions for lentiviral vector, suppling suspension and adherent platforms for
lentiviral vector production. The performance of the suspension platform is comparable
with the adherent one. The platforms consist of serum-free cultured suspension
HEK293 cell line with clear source, and in-house patented packaging plasmid
system that is adaptable for different transgenes. Our lentiviral vector
production is easy to scale up, and ensures high titer, high infectious
efficiency and low residual. With a wealth of experience, OBiO supports our
clients from IND to commercial manufacturing. Notably, OBiO already have
assisted BIOHENG in obtaining IND approval for their UCAR-T product, which is
the first "off-the-shelf" CAR-T product entering clinical trials in
China.</span> 
</p>
<p style="text-align:justify;">
	<br>
</p>
<p style="text-align:justify;">
	<strong><span style="font-size:16px;">About OBiO Technology</span></strong> 
</p>
<p style="text-align:justify;">
	<span style="font-size:16px;">&nbsp; &nbsp; OBiO Technology (Shanghai) Corp., Ltd. (OBiO, 688238.SH) is a gene and cell therapy-focused CRO and CDMO founded in 2013. For global customers, we offer holistic research, development, and manufacturing solutions for vectorology studies, functional genomics, process and analytical development, IND-enabling CMC, clinical and commercial manufacturing. With "enable gene therapy for better lives" as our mission, we are committed to providing high-quality service to global customers, advancing your product from bench to clinic, and bringing benefit to populations around the world. For more information about OBiO Technology, visit www.obio-tech.com.</span> 
</p>                </div>`,
  },
  {
    id: 5,
    type: "news",
    title: `OBiO and CHINAGENE reached a strategic agreement of commercial manufacturing services for gene therapy products`,
    time: "29th Apr. ,2023",
    subhead: "",
    content: ``,
    html: `<div class="Insights-detail-text text">
                   <p class="MsoNormal" style="text-align:justify;">
	<span style="font-family:&quot;font-size:16px;">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="font-family:&quot;font-size:16px;">On April</span><span style="font-family:&quot;font-size:16px;line-height:1.5;"></span><span style="font-family:&quot;font-size:16px;line-height:1.5;"></span><span style="font-family:&quot;font-size:16px;"> 21, 2023, OBiO Technology (Shanghai) Corp., Ltd. (OBiO) announced a strategic agreement of commercial manufacturing collaboration with CHINAGENE. Under the agreement, OBiO will provide holistic contract development and manufacturing services to CHINAGENE for their gene therapy products, including large-scale cGMP manufacturing service for clinical trials, process characterization and validation services, product formulation and filling services, and commercial manufacturing. In addition, OBiO and CHINAGENE will continue to expand the cooperation in academic communication globally, to promote the innovation of gene therapy.</span> 
</p>
<p class="MsoNormal" style="text-align:justify;">
	<span style="font-family:&quot;font-size:16px;"><br>
   </span> 
</p>
<p class="MsoNormal" style="text-align:justify;">
	<span style="font-size:16px;"></span> 
</p>
<p class="MsoNormal" style="text-align:center;">
	<img src="${handleViteImages("uploads/image/20230503/20230503234927_10504.jpg")}" alt=""> 
</p>
<p class="MsoNormal" style="text-align:justify;">
	<br>
</p>
<p class="MsoNormal" style="text-align:justify;">
	<span style="font-size:16px;"></span> 
</p>
<p class="MsoNormal" style="text-align:justify;">
	<span style="font-family:&quot;font-size:16px;">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="font-family:&quot;font-size:16px;">"This agreement signed by OBiO and CHINAGENE is a continuation and sublimation from previous cooperation", Guodong Jia, CEO of OBiO said, "CHINAGENE is a leading biotech among the ophthalmic gene therapy developer. OBiO is a leading gene and cell therapy CDMO in China. OBiO will continue to improve the capability of process development and cGMP management system, to promote the gene therapy product of CHINAGENE."</span> 
</p>
<p class="MsoNormal" style="text-align:justify;">
	<span style="font-size:16px;"></span> 
</p>
<p class="MsoNormal" style="text-align:justify;">
	<br>
</p>
<p class="MsoNormal" style="text-align:justify;">
	<span style="font-family:&quot;font-size:16px;">&nbsp;&nbsp;&nbsp;&nbsp;"OBiO has
abundant experience in gene therapy manufacturing and cGMP quality</span><span style="font-family:&quot;font-size:16px;">、</span><span style="font-family:&quot;font-size:16px;">management.
We are happy to continue our collaboration to accelerate the commercialization
of our ophthalmic gene therapy product ZVS101e." Xi Chen, the Vice
President of CHINAGENE said, "In past, OBiO had helped us to get the
investigational new drug (IND) approvals from National Medical Products
Administration of China (NMPA) and the U.S. Food and Drug Administration (FDA).
In future, we will continue to work closely with our own abilities, to help
more patients. "</span> 
</p>
<p>
	<span style="font-size:16px;"></span> 
</p>
<p class="MsoNormal" style="text-align:justify;">
	<br>
</p>
<p class="MsoNormal" style="text-align:justify;">
	<span style="font-family:&quot;font-size:16px;">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="font-family:&quot;font-size:16px;">On August 2021, ZVS101e, a gene therapy production from CHINAGENE, was authorized by the U.S. Food and Drug Administration (FDA) as an orphan drug. Data from an exploratory clinical trial (IIT) of ZVS101e for bietti crystalline dystrophy (BCD disease) showed good safety and efficacy. In December 2022, ZVS101e was approved to conduct the Investigational New Drug (IND approval) clinical trials for the treatment of crystallization-like retinitis pigmentosa caused by CYP4V2 biallelic mutations, by NMPA and FDA.</span> 
</p>
<p class="MsoNormal" style="text-align:justify;">
	<span style="font-family:&quot;font-size:16px;line-height:1.5;"><br>
    </span> 
</p>
<p class="MsoNormal" style="text-align:justify;">
	<span style="font-size:16px;"></span> 
</p>
<p class="MsoNormal" style="text-align:justify;">
	<span style="font-family:&quot;font-size:16px;"><strong>About CHINAGENE TECH</strong></span> 
</p>
<p class="MsoNormal" style="text-align:justify;">
	<span style="font-family:Times New Roman;"><span style="font-family:&quot;font-size:16px;">&nbsp;&nbsp;</span><span style="font-size:16px;line-height:1.5;font-family:&quot;">&nbsp;&nbsp;</span></span><span style="font-family:&quot;font-size:16px;">CHINAGENE TECH is a developer of clinical genetic diagnosis, fertility prevention and gene therapy drug for hereditary eye diseases. The company specializes in developing ophthalmic gene therapy drugs backed by accurate gene diagnosis, providing reliable ophthalmic gene pharmaceuticals for the public.</span> 
</p>
<p class="MsoNormal" style="text-align:justify;">
	<span style="font-family:&quot;font-size:16px;line-height:1.5;"><br>
    </span> 
</p>
<p class="MsoNormal" style="text-align:justify;">
	<span style="font-size:16px;"></span> 
</p>
<p class="MsoNormal" style="text-align:justify;">
	<span style="font-family:&quot;font-size:16px;"><strong>About OBiO Technology</strong></span> 
</p>
<p class="MsoNormal" style="text-align:justify;">
	<span style="font-family:&quot;font-size:16px;">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="font-family:&quot;font-size:16px;">OBiO Technology (Shanghai) Corp., Ltd. (OBiO, SSE:688238.SH) is a gene and cell therapy-focused biotechnology company founded in 2013. In&nbsp;China&nbsp;for global customers, we offer holistic research, development, and manufacturing solutions for vectorology studies, functional genomics, process and analytical development, IND-enabling CMC, clinical and commercial manufacturing. With "enable gene therapy for better lives" as our mission, we are committed to providing high-quality service to global customers, advancing your product from bench to clinic, and bringing benefit to populations around the world. For more information about OBiO, visit&nbsp;</span><a href="http://www.obio-tech.com/"><span style="font-family:&quot;font-size:16px;">www.obio-tech.com</span></a><span style="font-family:&quot;font-size:16px;">.</span> 
</p>
<p class="MsoNormal" style="text-align:justify;">
	<span style="font-family:&quot;font-size:16px;"><br>
    </span> 
</p>
<p class="MsoNormal" style="text-align:justify;">
	<span style="font-family:&quot;font-size:16px;line-height:1.5;"></span> 
</p>
<p class="MsoNormal" style="text-align:justify;">
	<span style="font-family:&quot;font-size:16px;">&nbsp;&nbsp;&nbsp;&nbsp;In&nbsp;the 26th
annual meeting of American Society for Gene and Cell Therapy (ASCGT), OBiO will
present the progress of in-house discovery regarding noval gene vectors, and
advanced process development. OBiO will hold 2 oral presentations and 5 posters
in the meeting. Welcome to OBiO's booth (#747) to get more information or
attend our oral presentation in room 515AB on May 16&nbsp;th 1:45pm to 2:00pm</span><span style="font-family:&quot;font-size:16px;">，</span><span style="font-family:&quot;font-size:16px;">other one is
room 511 on May 17th. We also have 5 posters (#1644, #1445, #940, #871</span><span style="font-family:&quot;font-size:16px;">，</span><span style="font-family:&quot;font-size:16px;">#792) to
show our innovation.</span> 
</p>
<p class="MsoNormal" style="text-align:justify;font-size:10.5pt;font-family:DengXian;">
	<span style="font-family:&quot;font-size:14px;"></span> 
</p>
<span style="font-size:medium;"></span>                </div>`,
  },
  {
    id: 6,
    type: "news",
    title: `A new super factory with 29 GMP grade production lines for gene and cell therapy was launched in Shanghai by OBiO technology`,
    time: "24th Apr. ,2023",
    subhead: "",
    content: ``,
    html: `<div class="Insights-detail-text text">
                   <p class="MsoNormal" style="text-align:justify;margin-left:10pt;">
	<span style="font-size:16px;">&nbsp;&nbsp;&nbsp;&nbsp;On April 21, 2023, OBiO Technology (Shanghai) Corp.,
Ltd. ("OBiO" or "the Company"), a leading gene and cell
therapy CDMO in China, announced the launching of a new GMP manufacturing base,
named OBiO Intelli-M. The new base was located in the China (Shanghai) Pilot
Free Trade Zone, Lin-Gang Special Area, with 29 production lines and 828,000+
square feet in area, which was one of the biggest super factories for gene
therapy in the world.</span>
</p>
<p class="MsoNormal" style="text-align:justify;margin-left:10pt;">
	<br>
</p>
<p class="MsoNormal" style="text-align:justify;margin-left:10pt;">
	<span style="font-size:16px;">&nbsp;&nbsp;&nbsp;&nbsp;At the opening
ceremony, OBiO showed the holistic process development capability and
large-scale GMP manufacturing capacity in variety gene and cell therapies.
According to OBiO's introduction, OBiO Intelli-M contains 11 different vector production
lines from Cytiva, Sartorius, ThermoFisher, Austar, for different kind of gene
vector manufacturing. These lines include manufacturing processes with cell
factory, roller bottle, fixed-bed, and 50 L/200 L/250 L/500 L/1000 L/2000 L
single-use bioreactor. Meanwhile, OBiO Intelli-M have 18 cell production lines
for&nbsp;autologous and allogeneic immune cell therapies and stem cell
therapies, in which 3 complete independence lines are used for cell therapies
in infectious disease patient. OBiO Intelli-M will continue to provide the
holistic contract research services and contract development and manufacturing
services (i.e. CRO/CDMO) to global clients in gene and cell therapies, with
one-stop solution from proof of concept, IND declaration, new drug application,
to commercial manufacturing, to accelerate gene and cell therapy.</span>
</p>
<p class="MsoNormal" style="text-align:justify;margin-left:10pt;">
	<br>
</p>
<p class="MsoNormal" style="text-align:center;margin-left:10pt;">
	<img src="${handleViteImages("uploads/image/20230427/20230427094849_44959.jpg")}" alt=""> 
</p>
<p class="MsoNormal" style="text-align:justify;margin-left:10pt;">
	<br>
</p>
<p class="MsoNormal" style="text-align:justify;margin-left:10pt;">
	<span style="font-size:16px;">&nbsp;&nbsp;&nbsp;&nbsp;Founded in 2013 and headquartered in
Shanghai, OBiO is a biotechnology company focusing on gene and cell therapy
field: serving as a contract research organization for vectorology and
functional genomics studies and providing contract development and
manufacturing services of IND-enabling CMC, clinical and commercial
manufacturing. In recent years, in line with the mission of 'enabling gene
therapy for better lives', OBiO has established core technologies around
vectorology development, large-scale process development and manufacturing,
facilitating a robust and versatile GMP manufacturing system for various gene
and cell therapy products. With the policy supports on gene therapy and
CRO/CDMO industry, OBiO has achieved a sustainable growth in market size.</span>
</p>
<p class="MsoNormal" style="text-align:justify;margin-left:10pt;">
	<br>
</p>
<p class="MsoNormal" style="text-align:justify;margin-left:10pt;">
	<span style="font-size:16px;">&nbsp;&nbsp;&nbsp;&nbsp;"Under the situation of the rapid
development of gene and cell therapy, large-scale GMP viral vector
manufacturing the foundation and key for the clinical applications of gene and
cell therapy, as well as the bottleneck of gene therapy industry." said
Oudong Pan, Chairman of OBiO. "The completion of OBiO Intelli-M, is a
critical milestone for the development of OBiO technology, as well as for the
gene therapy."</span>
</p>
<p class="MsoNormal" style="text-align:justify;margin-left:10pt;">
	<br>
</p>
<p class="MsoNormal" style="text-align:justify;margin-left:10pt;">
	<span style="font-size:16px;">&nbsp;&nbsp;&nbsp;&nbsp;Driven by technical innovations, policy
encouragements, and capital promotions, gene and cell therapy has gradually
entered a "golden age" of commercialization. As of the end of 2022,
more than 20 gene therapy drugs have been approved and entered clinical
applications globally. According to the Landscape Report 2022Q4 from ASGCT, 284
gene therapy pipelines were entered into phase II clinical trials or later. At
the same time, according to J.P. Morgan, due to the typical high technological
barriers and strict regulatory policy characteristics of gene therapy
development, the rate of gene and cell therapy outsourcing has exceeded 65%.
With the sustained rapid growth of the global CGT market in the future, CDMO
(contract development and manufacturing organization) companies will also rise
to the occasion and are expected to fully share the industry's high-speed
growth dividends.</span>
</p>
<p class="MsoNormal" style="text-align:justify;margin-left:10pt;">
	<br>
</p>
<p class="MsoNormal" style="text-align:justify;margin-left:10pt;">
	<span style="font-size:16px;">&nbsp;&nbsp;&nbsp;&nbsp;"Innovative is always the 'engine' for
drug discovery and human health. Thus, investments in biomedicine is the
eternal hot spots." said Peimin Zong, founder &amp; chairman of SINOWISDOM
investment, one the earliest investors to OBiO, "With the mission of
'enable gene therapy for better lives', OBiO will continue to serve clients
from all over the world, and will expand their service abilities with the
supporting of this new base."</span>
</p>
<p class="MsoNormal" style="text-align:justify;margin-left:10pt;">
	<br>
</p>
<p class="MsoNormal" style="text-align:justify;margin-left:10pt;">
	<span style="font-size:16px;">&nbsp;&nbsp;&nbsp;&nbsp;In future, with the new base, the
manufacturing capacity of OBiO technology will be greatly increased to meet the
increased demands. At the opening ceremony, OBiO reached strategic cooperation
in commercial manufacturing services with ImmVira, a leading biotech focused on
development of new generation novel anti-cancer drugs, and CHINAGENE THCH, a
leading AAV-based therapeutics developer. Moreover, OBiO and HOPE FOR RARE
FOUNDATION reached the agreement on comprehensively cooperation to promote the
clinical transformation of advanced therapies.</span>
</p>
<p class="MsoNormal" style="text-align:justify;margin-left:10pt;">
	<br>
</p>
<p class="MsoNormal" style="text-align:justify;margin-left:10pt;">
	<strong><span style="font-size:16px;">About OBiO technology</span></strong> 
</p>
<p class="MsoNormal" style="text-align:justify;margin-left:10pt;">
	<span style="font-size:16px;">&nbsp;&nbsp;&nbsp;&nbsp;OBiO Technology (Shanghai) Corp., Ltd. is a
gene and cell therapy-focused biotechnology company founded in 2013. In China
for global customers, OBiO offer holistic research, development, and
manufacturing solutions for vectorology studies, functional genomics, process
and analytical development, IND-enabling CMC, clinical and commercial
manufacturing. "Enable gene therapy for better life" as our mission,
OBiO are committed to providing high-quality service to global customers,
advancing your product from bench to clinic, and bringing benefit to
populations around the world. With many years of experience and expertise
accumulated in gene and cell therapy, OBiO has gained the recognition of
well-known enterprises and first listed company in the field. As to April 1th,
the Company has participated in and supported more than 150 gene and cell
therapy programs, 20+ of these programs have been approved to the clinical
trials, covering the gamut from plasmids, mRNA, AAV vector, oncolytic virus, immune
cell therapy, stem cells and other genetic medicines.</span>
</p>
<p class="MsoNormal" style="text-align:justify;margin-left:10pt;">
	<br>
</p>
<p class="MsoNormal" style="text-align:justify;margin-left:10pt;">
	<strong><span style="font-size:16px;">About OBiO TECH (Branch in the USA)</span></strong> 
</p>
<p class="MsoNormal" style="text-align:justify;margin-left:10pt;">
	<span style="font-size:16px;">&nbsp;&nbsp;&nbsp;&nbsp;OBiO TECH, INC is located in Milpitas,
California. This site is launched in February 2023 and covers 3,500 sq.ft. This
site includes R&amp;D team and business development team. BD team is led by
senior BD with dozens of years experiences in therapeutic\pharma industry.
R&amp;D team is led by experts in gene &amp; cell therapy field with dozens of
years academic and industry experiences. This branch will expand global
business to meet customer needs and build up international research collaboration
in gene &amp; cell therapy field.</span>
</p>
<p class="MsoNormal" style="text-align:justify;margin-left:10pt;">
	<br>
</p>
<p class="MsoNormal" style="text-align:justify;margin-left:10pt;">
	<span style="font-size:16px;">For more information, please visit </span><a href="http://www.obio-tech.com/"><span style="font-size:16px;">www.obio-tech.com</span></a> 
</p>
<p class="MsoNormal">
	<br>
</p>                </div>`,
  },
  {
    id: 7,
    type: "news",
    title: `Congratulations to immvira’s for its malignant glioma oncolytic product approved`,
    time: "31st Mar. ,2023",
    subhead: "",
    content: ``,
    html: `<div class="Insights-detail-text text">
                   <p style="text-align:justify;">
	<span style="font-size:16px;">&nbsp;&nbsp;&nbsp;&nbsp;On March 29, 2023, ImmVira announced that its oncolytic virus product MVR-C5252
targeting malignant glioma obtained the approval from National Medical Products
Administration ("NMPA") for Phase I
clinical trial in China. Previously, MVR-C5252 was granted orphan drug qualification
by the U.S. Food and Drug Administration in August 2022. OBiO Technology would like to express its heartfelt congratulations to
its partners for their important progress.</span>
</p>
<p style="text-align:justify;">
	<br>
</p>
<p style="text-align:center;">
	<img src="${handleViteImages("uploads/image/20230331/20230331142205_79082.jpg")}" alt=""> 
</p>
<p style="text-align:justify;">
	<br>
</p>
<p class="MsoNormal" align="left" style="text-align:justify;">
	<strong><em><span style="font-size:16px;">Relevant Reading：</span><span><a href="https://www.immviragroup.com/news/545.html" target="_blank"></a><a href="https://www.immviragroup.com/news/545.html" target="_blank"><strong><em><span style="font-size:16px;">【Customer Dynamics】Congratulation | The product MVR-C5252 from ImmVira, a new oncolytic virus product targeting glioma, has been granted "orphan drug" designation by the US FDA.&nbsp;</span></em></strong></a></span></em></strong><strong><em><span><a href="https://www.immviragroup.com/news/545.html" target="_blank"></a></span></em></strong> 
</p>
<p class="MsoNormal" align="left" style="text-align:justify;">
	<br>
</p>
<p class="MsoNormal" align="left" style="text-align:justify;">
	<span style="font-size:16px;">&nbsp;&nbsp;&nbsp;&nbsp;In July 2022, the Company
entered into a cooperative agreement with China Resource Biopharma
("CRBio") to jointly develop MVR-C5252 in the Greater China area,
leveraging CRBio's rich clinical resources to accelerate clinical progress. The
Company is also planning to jointly carry out clinical research on MVR-C5252
with Duke University in the U.S., and for the first time to use Convection
Enhanced Delivery ("CED") as the administration method. Diversified
cooperation modes not only reflect the recognition of ImmVira's oncolytic virus
products by well-known domestic and foreign pharmaceutical companies and
leading scientific research institutions, but also facilitate the Company's
clinical development in both China and the U.S., striving to provide new
treatment options for tumor patients as soon as possible.</span>
</p>
<p class="MsoNormal" align="left" style="text-align:justify;">
	<br>
</p>
<p class="MsoNormal" align="left" style="text-align:justify;">
	<span style="font-size:16px;">&nbsp;&nbsp;&nbsp;&nbsp;Malignant glioma has a
poor prognosis with a high recurrence rate of nearly 100% and a median survival
time of only 1.5 years, creating urgent needs for a more effective treatment
option. Developed on ImmVira's OVPENS (Open Vector + Potent, Enabling, Novel
&amp; Safe) platform, MVR-C5252 is designed specifically for the treatment of
central nervous system tumors. This product has been further precisely
attenuated to achieve on-target malignant gliocyte killing while maintaining
safety profile; and the product also carries specific therapeutic exogenous
genes to promote the immune response of tumor microenvironment for further
anti-tumor activity. On June 11, 2021, Daiichi Sankyo Company, Limited's
oncolytic therapy Delytact received conditional and time-limited approval from
the Ministry of Health, Labor and Welfare of Japan (MHLW), for the treatment of
malignant glioma, becoming the world's first OV therapy approved for brain
tumors and another strong validation of HSV-1 modality.</span>
</p>
<p class="MsoNormal" align="left" style="text-align:justify;">
	<br>
</p>
<p class="MsoNormal" align="left" style="text-align:justify;">
	<strong><em><span style="font-size:16px;">Original link of News details：</span></em></strong><a href="https://www.immviragroup.com/news/558.html" target="_blank"><strong><em><span style="font-size:16px;">ImmVira's oncolytic product MVR-C5252 targeting malignant glioma obtained NMPA's approval for Clinical Trial in China</span></em></strong></a> 
</p>
<p style="text-align:justify;">
	<a href="https://www.immviragroup.com/news/558.html" target="_blank"><br>
            </a> 
</p>
<p style="text-align:justify;">
	<strong><span style="font-size:16px;">About ImmVira</span></strong> 
</p>
<p style="text-align:justify;">
	<span style="font-size:16px;">&nbsp;&nbsp;&nbsp;&nbsp;ImmVira is a biotechnology company focused on developing and synthesizing biological vector delivery platform. The company has constructed a fully integrated OVPENS (Open Vector+ Potent, Enabling, Novel &amp; Safe) platform with solid science, technology and CMC know-how, and three derivative subplatforms including Oncolytic Virus, Cancer Vaccine and Biosynthetic Exosome, to support ongoing R&amp;D, clinical studies and commercialization of best-in-class mono and combo therapies driven by clinical benefits in oncology and non-oncology fields.</span>
</p>
<p style="text-align:justify;">
	<br>
</p>
<p style="text-align:justify;">
	<strong><span style="font-size:16px;">About OBiO Technology</span></strong> 
</p>
<p class="MsoNormal" align="left" style="text-align:justify;">
	<span style="font-size:16px;">&nbsp;&nbsp;&nbsp;&nbsp;OBiO Technology (Shanghai) Corp., Ltd. (OBiO, 688238.SH) is a gene and cell therapy-focused CRO and CDMO founded in 2013. For global customers, we offer holistic research, development, and manufacturing solutions for vectorology studies, functional genomics, process and analytical development, IND-enabling CMC, clinical and commercial manufacturing. With "enable gene therapy for better lives" as our mission, we are committed to providing high-quality service to global customers, advancing your product from bench to clinic, and bringing benefit to populations around the world. For more information about OBiO Technology, visit www.obio-tech.com.</span>
</p>                </div>`,
  },
  {
    id: 8,
    type: "news",
    title: `FDA Accepts GMP Plasmid DMF of OBiO Technology`,
    time: "16th Jan. ,2023",
    subhead: "",
    content: ``,
    html: `<div class="Insights-detail-text text">
                   <p style="text-align:justify;">
	<span style="font-size:16px;line-height:1.5;">&nbsp; &nbsp;&nbsp;</span><span style="font-size:16px;line-height:1.5;">OBiO Technology (Shanghai) Corp., Ltd. ('OBiO', 688238.SH), a gene and cell therapy-focused contract research organization (CRO) and contract development and manufacturing organization (CDMO), recently announced that the United States Food and Drug Administration (FDA) has accepted its GMP plasmid DNA drug master file (DMF), DMF Number 037766. The DMF acceptance enables a direct reference for investigational new drug (IND) filing for lentiviral vectors, autologous cell therapy, allogeneic cell therapy and stem cell therapy products, and helps shorten the communication, review and evaluation time to accelerate the filing of related products.</span>
</p>
<p style="text-align:justify;">
	<span style="font-size:16px;line-height:1.5;"><br>
</span>
</p>
<p style="text-align:justify;">
	<span style="line-height:1.5;"></span> 
</p>
<p style="text-align:justify;">
	<span style="font-size:16px;line-height:1.5;">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="font-size:16px;line-height:1.5;">DMF is a submission to the FDA by the holder that contains confidential information about the facilities, processes or articles used in the manufacturing, handling, packaging and storage. DMF policy facilitates an optimized solution for pharmaceutical companies, drug manufacturers and regulatory agencies. Drug manufacturers are permitted to submit the DMF information to the FDA without having to disclose the technical secrets. In addition, drug developers could be authorized to reference all or part of the content of a DMF in support of its IND application, thus saving time and communication costs for the application filing process.</span> 
</p>
<p style="text-align:justify;">
	<br>
</p>
<p style="text-align:justify;">
	<span style="font-size:16px;line-height:1.5;">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="font-size:16px;line-height:1.5;">In 2022, OBiO successfully supported its clients to obtain 12 IND clearances, including 3 FDA IND approvals, and 13 IND filing acceptances in total. With years of successful IND-supporting experience in China and the United States for various gene and cell therapy products, OBiO leverages valuable know-how in IND-enabling chemistry, manufacturing and control (CMC) services to offer its clients a faster and more reliable access to manufacturing and regulatory filing, thereby advancing gene therapy, cell therapy and oncolytic virotherapy products from bench to clinic and bringing benefit to more patient populations.</span> 
</p>
<p style="text-align:justify;">
	<br>
</p>
<p style="text-align:justify;">
	<span style="font-size:16px;line-height:1.5;">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="font-size:16px;line-height:1.5;">"The acceptance of DMF filing for our GMP plasmid relies on the experienced technical team and established quality system of OBiO, and it will further enable us to provide clients with holistic CDMO solutions from DNA to IND," said Dr. Qingrui You, Vice General Manager of OBiO. "OBiO has been supporting its clients in IND applications for the adeno-associated virus, CAR-T therapy, stem cells, and oncolytic virus with high quality, all-inclusive CMC services from bank construction to GMP production. We are filing DMFs with the FDA for other products, and will continue to invest in a pipeline of innovations from manufacturing technology to process development and quality control."</span> 
</p>
<p style="text-align:justify;">
	<br>
</p>
<p style="text-align:justify;">
	<span style="font-size:16px;line-height:1.5;">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="font-size:16px;line-height:1.5;">In 2020, OBiO has built the OBiO Intelli-M site, a 77,000 m2 (828,821 ft²) GMP production base with global service capability in the Lin-gang Special Area of China (Shanghai) Pilot Free Trade Zone, which will be put into trial operation in Q1 of 2023. In this zone, OBiO will empower the development of global gene and cell therapy through the construction of a world-class facility of 15 vector production lines covering capacities from 50 to 2,000L, 11 cell therapy production lines, and 3 cell therapy production lines for pathogen carriers.</span> 
</p>
<div style="text-align:justify;">
	<br>
</div>
<p style="text-align:justify;">
	<strong><span style="font-size:16px;line-height:1.5;">About OBiO Technology</span></strong> 
</p>
<p style="text-align:justify;">
	<span style="font-size:16px;line-height:1.5;">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="font-size:16px;line-height:1.5;">OBiO Technology (Shanghai) Corp., Ltd. (OBiO, 688238.SH) is a gene and cell therapy-focused CRO and CDMO founded in 2013. For global customers, we offer holistic research, development, and manufacturing solutions for vectorology studies, functional genomics, process and analytical development, IND-enabling CMC, clinical and commercial manufacturing. With "enable gene therapy for better lives" as our mission, we are committed to providing high-quality service to global customers, advancing your product from bench to clinic, and bringing benefit to populations around the world. For more information about OBiO Technology, visit www.obio-tech.com.</span> 
</p>
 <span style="font-size:14px;line-height:2;"></span>                </div>`,
  },
  {
    id: 9,
    type: "news",
    title: `OBiO Technology to Present Data on OVersatile™ Platform for Process Development of Herpes Simplex Virus and Vaccinia Virus Products at the 25th ASGCT Annual Meeting`,
    time: "9th May ,2022",
    subhead: "",
    content: ``,
    html: `<div class="Insights-detail-text text">
                   <p>
	<span style="font-size:16px;">&nbsp;&nbsp;&nbsp;&nbsp;OBiO Technology (Shanghai)
 Corp., Ltd. ('OBiO', SSE:688238.SH), a gene and cell therapy-focused 
biotechnology company, serving as a contract research organization for 
vectorology and functional genomics studies, and providing contract 
development and manufacturing services of IND-enabling CMC, clinical and
 commercial manufacturing, today announced that research on novel 
manufacturing technologies via its OVersatile™&nbsp;platform will be 
presented at the American Society of Gene &amp; Cell Therapy (ASGCT) 
25th Annual meeting on May 16-19, 2022 in Washington, D.C.</span>
</p>
<p>
	<br>
</p>
<p style="text-align:center;">
	<span style="font-size:16px;"></span><img src="${handleViteImages("uploads/image/20220513/20220513114200_82491.png")}" alt="" title="" width="598" height="173" align=""><span style="font-size:16px;">&nbsp;</span>
</p>
<p>
	<br>
</p>
<p>
	<span style="font-size:16px;">&nbsp;&nbsp;&nbsp;&nbsp;Empowered by robust manufacturing technologies and a comprehensive 
quality control system, the OVersatile™&nbsp;platform enables flexible and 
high-quality process development and manufacturing solutions for a 
variety of gene and cell therapy products. Through research and 
development on novel manufacturing technologies with enhanced 
manufacturability, developability, and efficiency, the platform 
facilitates a high-titer, large-scale production capability and provides
 versatile development possibilities for various demands. The 
presentations highlight research on the upstream process development of 
herpes simplex virus and vaccinia virus products with the application of
 novel manufacturing technologies.</span>
</p>
<p>
	<br>
</p>
<p>
	<strong><span style="font-size:16px;">Details of the poster presentations:</span></strong>
</p>
<p>
	<span style="font-size:16px;">Title: Development of Scalable Vaccinia Virus-Based Vector Production Process Using Dissolvable Porous Microcarriers</span><br>
<span style="font-size:16px;">   Session Date/Time: Monday, May 16, 2022, 5:30 p.m. - 6:30 p.m. EST</span><br>
<span style="font-size:16px;">   Session Title: Vector Product Engineering, Development or Manufacturing I</span><br>
<span style="font-size:16px;">   Abstract Number: 414</span><br>
<span style="font-size:16px;">   Poster Board Number: M-295</span>
</p>
<p>
	<br>
</p>
<p>
	<span style="font-size:16px;">Title:&nbsp;High-Titer Herpes Simplex Virus Type 1-Based Vector Manufacturing Using Univercells Technologies' Production System</span><br>
<span style="font-size:16px;">   Session Date/Time: Tuesday, May 17, 2022 5:30 p.m. - 6:30 p.m. EST</span><br>
<span style="font-size:16px;">   Session Title: Vector Product Engineering, Development or Manufacturing II</span><br>
<span style="font-size:16px;">   Abstract Number: 768</span><br>
<span style="font-size:16px;">   Poster Board Number: Tu-273</span>
</p>
<p>
	<br>
</p>
<p>
	<strong><span style="font-size:16px;">About OBiO</span></strong> 
</p>
<p>
	<span style="font-size:16px;">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="font-size:16px;">OBiO Technology (Shanghai) Corp., Ltd. (OBiO, SSE:688238.SH) is a gene and cell therapy-focused biotechnology company founded in 2013. In China  for global customers, we offer holistic research, development, and 
manufacturing solutions for vectorology studies, functional genomics, 
process and analytical development, IND-enabling CMC, clinical and 
commercial manufacturing. With "enable gene therapy for better lives" as
 our mission, we are committed to providing high-quality service to 
global customers, advancing your product from bench to clinic, and 
bringing benefit to populations around the world. For more information 
about OBiO, visit </span><a href="http://www.obio-tech.com"><span style="font-size:16px;">www.obio-tech.com</span></a><span style="font-size:16px;">.</span>
</p>
<p>
	<br>
</p>                </div>`,
  },
  {
    id: 10,
    type: "news",
    title: `OBiO Technology Goes Public on Shanghai Stock Exchange Today`,
    time: "22nd Mar. ,2022",
    subhead: "",
    content: ``,
    html: `<div class="Insights-detail-text text">
                   <span style="line-height:1.5;">&nbsp;&nbsp;&nbsp;&nbsp;On March 22, 2022, OBiO Technology (Shanghai) Corp., Ltd. ("OBiO" or "the Company"), has completed its initial public offering ("IPO") process and started trading on the Shanghai Stock Exchange's Sci-Tech innovation board (SSE, code: 688238).</span><br>
 <br>
<div style="text-align:center;">
	<span style="line-height:1.5;"></span><img src="${handleViteImages("uploads/image/20220330/20220330171446_95206.png")}" alt=""> 
</div>
<br>
<p>
	<span style="line-height:1.5;">&nbsp;&nbsp;&nbsp;&nbsp;Founded in 2013 and headquartered in Shanghai, OBiO is a biotechnology company focusing on gene and cell therapy field: serving as a contract research organization for vectorology and functional genomics studies and providing contract development and manufacturing services of IND-enabling CMC, clinical and commercial manufacturing. In recent years, in line with the mission of enabling gene therapy for better life, OBiO has established core technologies around vectorology development, large-scale process development and manufacturing, facilitating a robust and versatile GMP manufacturing system for various gene and cell therapy products. With the policy supports on gene therapy and CRO/CDMO industry, OBiO has achieved a sustainable growth in market size.</span>
</p>
<p>
	<span style="line-height:1.5;"><br>
</span>
</p>
<p>
	<span style="line-height:1.5;">&nbsp;&nbsp;&nbsp;&nbsp;With many years of experience and expertise accumulated in gene and cell therapy, OBiO has become a leading company and gained the recognition of well-known enterprises and first-class universities in the field. The Company has participated in and supported more than 100 gene and cell therapy programs, covering the gamut from viral vector, oncolytic virus, chimeric antigen receptor (CAR) T-cell therapy and other genetic medicines.</span>
</p>
<p>
	<span style="line-height:1.5;"><br>
</span>
</p>
<p>
	<span style="line-height:1.5;">&nbsp;&nbsp;&nbsp;&nbsp;"The successful listing on Shanghai's STAR market is a major milestone clearly marking the company's entry into its next stage of growth," said Oudong Pan, Chairman of OBiO. "Looking forward, our core mission will continue to focus on research and development together with the technological enhancement of gene therapy vectorology while we further expand the technology clusters and strengthen the protection of our intellectual property. In addition, we plan to further optimize the business model, enhance our ability to integrate and participate in projects with like-minded firms worldwide, and continue our customer-centered approach to the provision of professional services, as we strive to transform OBiO into a leading international gene and cell therapy CRO/CDMO group."</span>
</p>
 <br>
 <span style="line-height:1.5;"><strong>About OBiO</strong></span><br>
<span style="line-height:1.5;">&nbsp;&nbsp;&nbsp;&nbsp;OBiO Technology (Shanghai) Corp., Ltd. (OBiO) is a gene and cell therapy-focused biotechnology company founded in 2013. For global customers, we offer holistic research, development, and manufacturing solutions for vectorology studies, functional genomics, process and analytical development, IND-enabling CMC, clinical and commercial manufacturing. "Enable gene therapy for better life" as our mission, we are committed to providing high-quality service to global customers, advancing your product from bench to clinic, and bringing benefit to populations around the world. For more information about OBiO, visit www.obiosh.com.</span><br>
 <br>
 <span style="line-height:1.5;">Contacts:</span><br>
<span style="line-height:1.5;">Jiaxin Wang (Esther)</span><br>
 <span style="line-height:1.5;">marketing@obiosh.com</span><br>
 <span style="line-height:1.5;">+86 400-151-5198</span><br>
 <span style="line-height:2;"></span><br>                </div>`,
  },
  {
    id: 11,
    type: "news",
    title: `OBiO Announces ASGCT 24th Annual Meeting Attendance`,
    time: "11st May ,2021",
    subhead: "",
    content: ``,
    html: `<div class="Insights-detail-text text">
                   <div style="text-align:justify;">
	<span style="font-size:16px;">&nbsp; &nbsp; OBiO Biotechnology (Shanghai) Corp. Ltd., (“OBiO” or “the Company”), announced it will be attending the American Society of Gene &amp; Cell Therapy (ASGCT) 24th Annual Meeting to be held virtually from May 11-14, 2021.</span>
</div>
<div style="text-align:justify;">
	<br>
</div>
<p style="text-align:center;">
	<img src="${handleViteImages("uploads/image/20220330/20220330171717_65357.png")}" alt=""> 
</p>
<p style="text-align:justify;">
	<br>
</p>
<p>
	<br>
</p>
<div style="text-align:justify;">
	<span style="font-size:16px;">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="font-size:16px;">Feel free to join the OBiO virtual booth livestream on May 11 and 13 from 10:30 a.m. to 12:00 p.m. EST, to learn more about gene and cell therapy market access in China and OBiO’s role as a CDMO to help biotech speed up their commercialization worldwide. Dr. Guodong Jia, General Manager of OBiO, will exchange and share insights on gene therapy product research and manufacturing with other global industry professionals around the world.</span>
</div>
<div style="text-align:justify;">
	<br>
</div>
<div style="text-align:justify;">
	<span style="font-size:16px;">To access the meeting, please visit: </span><a href="https://annualmeeting.asgct.org/" target="_blank"><em><span style="font-size:16px;">https://annualmeeting.asgct.org/</span></em></a>
</div>
<div style="text-align:justify;">
	<span style="font-size:16px;"></span><br>
</div>
<p style="text-align:left;">
	<span style="font-size:16px;">For OBiO’s pre-show listing, please visit:&nbsp;</span><a href="https://s36.a2zinc.net/clients/asgct/asgct2021https://www.obio-tech.com/public/eBooth.aspx?IndexInList=63&amp;FromPage=Exhibitors.aspx&amp;ParentBoothID=&amp;ListByBooth=true&amp;BoothID=100419" target="_blank"><em><span style="font-size:16px;">https://s36.a2zinc.net/clients/asgct/asgct2021https://www.obio-tech.com/public/eBooth.aspx?IndexInList=63&amp;FromPage=Exhibitors.aspx&amp;ParentBoothID=&amp;ListByBooth=true&amp;BoothID=100419</span></em></a>
</p>
 <span style="line-height:2;"></span><span style="line-height:2;"></span> 
<p>
	<br>
</p>                </div>`,
  },
  {
    id: 12,
    type: "news",
    title: `OBiO and QuaCell Biotechnology reached a strategic cooperation on the joint development of the Wayne293™ host cell platform and high-toxin-producing derivative cell lines`,
    time: "9th Mar. ,2021",
    subhead: "",
    content: ``,
    html: `<div class="Insights-detail-text text">
                   <p style="text-align:justify;">
	<span style="font-size:16px;">&nbsp; &nbsp; On March 9, 2021, OBiO Technology (Shanghai) Corp., Ltd. (hereinafter referred to as "OBiO") and QuaCell Biotechnology, Co., Ltd. (hereinafter referred to as "QuaCell") jointly announced a strategic cooperation intent on the joint development of the Wayne293™ host cell platform and high-toxin-producing derivative cell lines. This cooperation aims to complement each other's technological advantages, connect upstream and downstream, and provide more comprehensive, high-quality, and efficient technical services and solutions to cell and gene therapy customers worldwide.</span>
</p>
<p style="text-align:justify;">
	<span style="font-size:16px;"><br>
</span>
</p>
 <span style="line-height:1.5;"> 
<div style="text-align:justify;">
	<span style="font-size:16px;"></span> 
</div>
</span> 
<div style="text-align:center;">
	<span style="font-size:16px;"></span><img src="${handleViteImages("uploads/image/20220330/20220330171958_53632.png")}" alt=""> 
</div>
<div style="text-align:justify;">
	<span style="font-size:16px;"></span><br>
</div>
 <span style="line-height:1.5;"> 
<div style="text-align:justify;">
	<strong><span style="font-size:16px;">Cooperation Background</span></strong> 
</div>
</span><span style="line-height:1.5;"> 
<div style="text-align:justify;">
	<span style="font-size:16px;">&nbsp; &nbsp; </span><span style="font-size:16px;">OBiO is a leading domestic high-tech enterprise integrating basic biomedical research, gene therapy drug incubation, and clinical-grade gene therapy viral vector CDMO services. It has been deeply involved in gene function research and gene therapy subdivision for many years. Under international biopharmaceutical GMP standards, it has built a gene therapy vector manufacture platform that complies with China's NMPA, US FDA, EU EMA gene and cell therapy quality management specifications. OBiO has nearly 4,500 ㎡ of comprehensive gene carrier R&amp;D and production platform and more than 6,000 ㎡ of gene carrier GMP production platform. At the same time, it has started the construction of over 80,000m2 precision medical-industrial base (OBiO Intelli-M) at Lin-Gang Special Area, Shanghai Pilot Free Trade Zone. OBiO provides global gene and cell therapy scientists, medical units, and drug research and development companies with CDMO services for gene and cell therapy plasmids, adeno-associated viruses, lentiviruses, adenoviruses, a variety of oncolytic viruses, and cell therapy products. It strives to promote gene therapy's clinical application in the whole process, from gene sequence to gene medicine.</span> 
</div>
</span> 
<div style="text-align:justify;">
	<br>
</div>
  <span style="line-height:1.5;"> 
<div style="text-align:justify;">
	<span style="font-size:16px;">&nbsp; &nbsp; </span><span style="font-size:16px;">QuaCell is a rapidly growing global biotechnology enterprise headquartered in Zhongshan City, Guangdong-Hong Kong-Macao Greater Bay Area. We provide our clients with innovative biopharmaceutical service solutions in our approximately 7,000 ㎡ facility that fully integrates culture medium development and production, cell line development, and GMP pilot-scale production. Complying with ISO and GMP regulations, QuaCell focuses on the research and manufacture of cell culture media and provides necessary raw materials for global biopharmaceutical and gene therapy companies. QuaCell delivers the first and only fully freely implemented CHO-K1 host cell platform in China-QuaCell® CHO-K1Q. In the past two years, QuaCell has provided nearly 50 antibody-protein drug companies in China, solving traceability and authorization pain points. Given this successful experience, QuaCell and the founder of the 293 cell line, Professor Frank Graham, signed an exclusive sub-licensing agreement for 293 background intellectual property rights in Greater China to legally and compliantly introduce the original HEK293 cells and develop a series of derivative cell lines. We are committed to being a cell and gene therapy partner to solve the problems of 293 cell import, traceability, authorization, and viral packaging industrialization.</span> 
</div>
</span> 
<div style="text-align:justify;">
	<br>
</div>
  <span style="line-height:1.5;"> 
<div style="text-align:justify;">
	<strong><span style="font-size:16px;">Cooperation Direction</span></strong> 
</div>
</span><span style="line-height:1.5;"> 
<div style="text-align:justify;">
	<span style="font-size:16px;">&nbsp; &nbsp; OBiO and QuaCell will carry out comprehensive strategic cooperation based on the Wayne293™ host cell platform (the original HEK293 cell platform acclimated in suspension) owned by QuaCell with clear traceability records and global commercial authorization. We will advance our work in the development of platform cell lines, the development &amp; optimization of culture media. Also, we will further rely on OBiO's technical advantages in gene and cell therapy to develop HEK293-derived cell lines for the production of high-titer viral vectors. We will work together to provide better host cells and commercial authorization to develop gene and cell therapy drugs.</span> 
</div>
</span> 
<div style="text-align:justify;">
	<br>
</div>
  <span style="line-height:1.5;"> 
<div style="text-align:justify;">
	<span style="font-size:16px;">&nbsp; &nbsp; Dr. Guodong Jia, General Manager of OBiO, said: "QuaCell is a well-known domestic biopharmaceutical company that focuses on the research, development, and production of biologics provides customers with high-quality cell products in core areas. This time, OBiO and QuaCell will further develop high-yield derivative cell lines based on the cooperation of the Wayne293™ host cell platform. Through the organic combination of their respective advantages, while promoting the gene and cell therapy industry's development, we can better realize making gene therapy benefits humankind. "</span> 
</div>
</span> 
<div style="text-align:justify;">
	<br>
</div>
  <span style="line-height:1.5;"> 
<div style="text-align:justify;">
	<span style="font-size:16px;">&nbsp; &nbsp; Dr. H. Fai Poon, CEO of QuaCell, said: "OBiO is an excellent enterprise in the field of CDMO in cell and gene therapy in China. It has leading technology and rich experience in the development and production of various viral vectors. Through the in-depth cooperation between the two parties, OBiO and QuaCell will work together as mutual customers and partners to solve the pain point of host cell commercialization authorization and traceability; also, we will cooperate in the R &amp; D of derivative cell strains required for the production of high-titer viral vectors, optimize the production process of viral vectors, etc., and jointly contribute to the acceleration of China's cell and gene therapy industry. "</span> 
</div>
</span> 
<div style="text-align:justify;">
	<br>
</div>
  <span style="line-height:1.5;"> 
<div style="text-align:justify;">
	<strong><span style="font-size:16px;">Cooperation Vision</span></strong> 
</div>
</span> 
<div style="text-align:justify;">
	<span style="font-size:16px;">&nbsp; &nbsp; Our strategic cooperation will promote the rapid development of the cell therapy and gene therapy industries in China. We will fully integrate our superior resources, provide high-quality products and services to our mutual customers and partners, accelerate gene therapy's entry into the application stage, and benefit humankind as soon as possible.</span> 
</div>                </div>`,
  },
]);

export const events = ref([
  {
    id: 9,
    type: "event",
    title: '2024 Global Rare Diseases Research Symposium & The Second China Rare Disease Research and Translational Medicine Annual Conference is coming soon',
    time: "May 20th 2024",
    img: handleViteImages("uploads/image/20240520/6281716217459_.pic.jpg"),
    subhead: "",
    content: '',
    eventTime: 'May 23-25, 2024',
    location: 'Primus Hotel Shanghai SanJiaGang, 6666 E Huaxia Rd #3, Pudong New district, Shanghai, China.',
    html: `<div class="Insights-detail-text text">
    <img src="${handleViteImages("uploads/image/20240520/6281716217459_.pic.jpg")}" alt="" class="center"/>
    <p style='margin-right:0in;margin-left:0in;font-size:16px;font-family:"Calibri",sans-serif;margin:0in;margin-bottom:.0001pt;'><br></p>
    <p style='margin-right:0in;margin-left:0in;font-size:16px;font-family:"Calibri",sans-serif;margin:0in;margin-bottom:.0001pt;'><span style='font-size:19px;font-family:"Verdana",sans-serif;color:black;background:white;'>The conference is co-hosted by #Hope for Rare Foundation, International Rare Diseases Research Consortium (IRDiRC)), and&nbsp;</span><span style='font-size:19px;font-family:"Microsoft YaHei",sans-serif;color:black;background:white;'>复旦大学</span><span style='font-size:19px;font-family:"Verdana",sans-serif;color:black;background:white;'>&nbsp;Fudan University.&nbsp;</span></p>
    <p style='margin-right:0in;margin-left:0in;font-size:16px;font-family:"Calibri",sans-serif;margin:0in;margin-bottom:8.0pt;margin-top:0in;'><span style='font-size:19px;font-family:"Verdana",sans-serif;color:black;background:white;'>&nbsp;</span></p>
    <p style='margin-right:0in;margin-left:0in;font-size:16px;font-family:"Calibri",sans-serif;margin:0in;margin-bottom:8.0pt;margin-top:0in;'><span style='font-size:19px;font-family:"Verdana",sans-serif;color:black;background:white;'>Time: May 23rd to 25th, details shown on the pictures</span></p>
    <p style='margin-right:0in;margin-left:0in;font-size:16px;font-family:"Calibri",sans-serif;margin:0in;margin-bottom:8.0pt;margin-top:0in;'><span style='font-size:19px;font-family:"Verdana",sans-serif;color:black;background:white;'>Location: Primus Hotel Shanghai SanJiaGang</span></p>
    <p style='margin-right:0in;margin-left:0in;font-size:16px;font-family:"Calibri",sans-serif;margin:0in;margin-bottom:8.0pt;margin-top:0in;'><span style='font-size:19px;font-family:"Verdana",sans-serif;color:black;background:white;'>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;6666 E Huaxia Rd #3</span><span style='font-size:19px;font-family:"Microsoft YaHei",sans-serif;color:black;background:white;'>，</span><span style='font-size:19px;font-family:"Verdana",sans-serif;color:black;background:white;'>Pudong New district, Shanghai, China.</span></p>
    <p style='margin-right:0in;margin-left:0in;font-size:16px;font-family:"Calibri",sans-serif;margin:0in;margin-bottom:8.0pt;margin-top:0in;'><span style='font-size:19px;font-family:"Verdana",sans-serif;color:black;background:white;'>&nbsp;</span></p>
    <img src="${handleViteImages("uploads/image/20240520/6291716217459_.pic.jpg")}" alt="" class="center"/>
    <p style='margin-right:0in;margin-left:0in;font-size:16px;font-family:"Calibri",sans-serif;margin:0in;margin-bottom:8.0pt;margin-top:0in;'><span style='font-size:19px;font-family:"Verdana",sans-serif;color:black;background:white;'>The conference will last for 2.5 days with 21 parallel sessions and several satellite meetings. It will bring together over 100 speakers from global universities, hospitals, academic institutions, and pharmaceutical companies. Topics will cover basic research on rare diseases, gene and cell therapies, Investigator Initiated Trials (IIT), clinical studies, drug development, and international research collaborations. The conference will present the latest developments and original findings in rare diseases research, highlighting China&rsquo;s contributions in the context of a global perspective</span></p>
    <img src="${handleViteImages("uploads/image/20240520/6301716217539_.pic.jpg")}" alt="" class="center"/>
    <p style='margin-right:0in;margin-left:0in;font-size:16px;font-family:"Calibri",sans-serif;margin:0in;margin-bottom:8.0pt;margin-top:0in;'><span style='font-size:19px;font-family:"Verdana",sans-serif;color:black;background:white;'>&nbsp;</span></p>
    <p style='margin-right:0in;margin-left:0in;font-size:16px;font-family:"Calibri",sans-serif;margin:0in;margin-bottom:8.0pt;margin-top:0in;'><span style='font-size:19px;font-family:"Verdana",sans-serif;color:black;background:white;'>Contact Information:</span></p>
    <p style='margin-right:0in;margin-left:0in;font-size:16px;font-family:"Calibri",sans-serif;margin:0in;margin-bottom:8.0pt;margin-top:0in;'><span style='font-size:19px;font-family:"Verdana",sans-serif;color:black;background:white;'>Rufang Huang +86 860-046-3832 kevin.huang@hope4rare.org.cn</span></p>
    <p style='margin-right:0in;margin-left:0in;font-size:16px;font-family:"Calibri",sans-serif;margin:0in;margin-bottom:8.0pt;margin-top:0in;'><span style='font-size:19px;font-family:"Verdana",sans-serif;color:black;background:white;'>Business Cooperation: Wenjun Zhang +86 133-7253-0505 wenjun.zhang@hope4rare.org.cn&nbsp;</span></p>
    <p style='margin-right:0in;margin-left:0in;font-size:16px;font-family:"Calibri",sans-serif;margin:0in;margin-bottom:8.0pt;margin-top:0in;'><span style='font-size:19px;font-family:"Verdana",sans-serif;color:black;background:white;'>Speaker Recommendations/Academic Collaboration</span><span style='font-size:19px;font-family:"Microsoft YaHei",sans-serif;color:black;background:white;'>：</span><span style='font-size:19px;font-family:"Verdana",sans-serif;color:black;background:white;'>Boya Yu +86 188-9854-8654 boya.yu@hope4rare.org.cn&nbsp;</span></p>
    <p style='margin-right:0in;margin-left:0in;font-size:16px;font-family:"Calibri",sans-serif;margin:0in;margin-bottom:8.0pt;margin-top:0in;'><span style='font-size:19px;font-family:"Verdana",sans-serif;color:black;background:white;'>Official Website: <a href="https://lnkd.in/gTRSfPfb" target="_blank" style="text-decoration: underline;">https://lnkd.in/gTRSfPfb</a></span></p>
    <p style='margin-right:0in;margin-left:0in;font-size:16px;font-family:"Calibri",sans-serif;margin:0in;margin-bottom:8.0pt;margin-top:0in;'><span style='font-size:19px;font-family:"Verdana",sans-serif;color:black;background:white;'>&nbsp;</span></p>
    <p style='margin-right:0in;margin-left:0in;font-size:16px;font-family:"Calibri",sans-serif;margin:0in;margin-bottom:8.0pt;margin-top:0in;'><span style='font-size:19px;font-family:"Verdana",sans-serif;color:black;background:white;'>#cgt #cellandgenetherapy #genetherapy #celltherapy #cdmo #2024trends #globaldata #asgct #viralvector #biotech #equipment #development #manufacturing</span></p></div>`
  },
  {
    id: 8,
    type: "event",
    title: `Meet OBiO Technology at ASGCT 2024! May 7th to 11th`,
    time: "April 27th 2024",
    img: handleViteImages("uploads/image/20240427/Picture1.png"),
    subhead: "",
    content: '',
    eventTime: 'May 7-11, 2024',
    location: 'Baltimore, Maryland, USA',
    html: `<div class="Insights-detail-text text">
    <img src="${handleViteImages("uploads/image/20240427/Picture1.png")}" alt="" class="center"/>
    <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:115%;font-size:16px;font-family:"Aptos",sans-serif;text-align:center;'><br></p>
    <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:normal;font-size:16px;font-family:"Aptos",sans-serif;text-align:center;'><strong><span style='font-size:32px;font-family:"Calibri",sans-serif;color:#0070C0;'>F</span></strong><strong><span style='font-size:32px;font-family:"Microsoft YaHei",sans-serif;color:#0070C0;'>ocus</span></strong><strong><span style='font-size:32px;font-family:"Calibri",sans-serif;color:#0070C0;'>-Acceleration-Standardization-Team</span></strong></p>
    <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:normal;font-size:16px;font-family:"Aptos",sans-serif;text-align:center;'><strong><span style='font-size:24px;font-family:"Calibri",sans-serif;color:#0070C0;'>Our FAST Commitment to Accelerate Your Success</span></strong></p>
    <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:115%;font-size:16px;font-family:"Aptos",sans-serif;'><span style='font-size:19px;line-height:115%;font-family:"Verdana",sans-serif;color:black;background:white;'>We are looking forward to ASGCT in Baltimore and excited to see you there! You&rsquo;re invited to stop&nbsp;</span><span style='font-size:19px;line-height:115%;font-family:"Verdana",sans-serif;color:#0070C0;background:white;'>by <strong>OBiO Tech booth #1644</strong></span>.</p>
    <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:115%;font-size:16px;font-family:"Aptos",sans-serif;'><span style='font-size:14px;line-height:115%;font-family:"-apple-system",serif;background:white;'>&nbsp;</span></p>
    <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:115%;font-size:16px;font-family:"Aptos",sans-serif;'><span style='font-size:19px;line-height:115%;font-family:"Verdana",sans-serif;color:black;background:white;'>We will present&nbsp;</span><strong><span style='font-size:19px;line-height:115%;font-family:"Verdana",sans-serif;color:#0070C0;background:white;'>9 posters</span></strong>. <span style='font-size:19px;line-height:115%;font-family:"Verdana",sans-serif;color:black;background:white;'>Among these presentations are three self-developed patented achievements, four notable advancements in process optimization, and two cutting-edge technology introductions.&nbsp;</span></p>
    <img src="${handleViteImages("uploads/image/20240427/Picture2.png")}" alt="" class="center" />
    <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:115%;font-size:16px;font-family:"Aptos",sans-serif;'><span style='font-size:19px;line-height:115%;font-family:"Verdana",sans-serif;color:black;background:white;'>These milestones exemplify OBiO Technology&apos;s significant strides in the gene therapy domain, enhancing vector yield and efficiency, refining therapeutic processes, and driving down production costs.</span></p>
    <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:115%;font-size:16px;font-family:"Aptos",sans-serif;'><span style='font-size:19px;line-height:115%;font-family:"Verdana",sans-serif;color:black;background:white;'>&nbsp;Our innovative solutions offer dependable and cost-effective production methods for gene therapy, propelling forward clinical projects in gene and cell therapy.&nbsp;</span></p>
    <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:115%;font-size:16px;font-family:"Aptos",sans-serif;'><span style='font-size:19px;line-height:115%;font-family:"Verdana",sans-serif;color:black;background:white;'>Our experts are ready to share how our comprehensive viral vector platform accelerates development timelines, de-risks manufacturing, and provides the performance and product quality needed for your success, with a lower cost.&nbsp;</span></p>
    <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:115%;font-size:16px;font-family:"Aptos",sans-serif;text-align:center;'><br></p>
    <a href="https://www.linkedin.com/feed/update/urn:li:activity:7187104691195985921"><img src="${handleViteImages("uploads/image/20240427/Picture3.png")}" alt="" class="center" /></a>
    <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:115%;font-size:16px;font-family:"Aptos",sans-serif;text-align:center;'><br></p>
    <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:115%;font-size:16px;font-family:"Aptos",sans-serif;'><span style='font-size:19px;line-height:115%;font-family:"Verdana",sans-serif;color:black;background:white;'>&nbsp;</span></p>
    <img src="${handleViteImages("uploads/image/20240427/Picture4.png")}" alt="" class="center" />
    <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:115%;font-size:16px;font-family:"Aptos",sans-serif;'><span style='font-size:19px;line-height:115%;font-family:"Verdana",sans-serif;color:black;background:white;'>Mr. Javier Jia Guo, CEO of OBiO Technology, expressed, &quot;We are delighted to continue our legacy of excellence at the ASGCT conference! OBiO Technology will participate with utmost enthusiasm and innovative prowess, showcasing our latest achievements in gene and cell therapy. Our nine presentations, featuring self-developed patented achievements, process optimization breakthroughs, and technology introductions, epitomize our commitment to relentless innovation and collaborative problem-solving. They also underscore our significant progress in enhancing yield efficiency, streamlining production processes, and driving cost efficiencies. OBiO Technology remains steadfast in its forward-looking technological layout and continuous improvement of service capabilities, contributing to the rapid advancement of the gene and cell therapy industry.&quot;</span></p>
    <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:115%;font-size:16px;font-family:"Aptos",sans-serif;'>&nbsp;</p>
    <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:115%;font-size:16px;font-family:"Aptos",sans-serif;text-align:center;'><br></p>
    <a href="https://www.youtube.com/@obiotechnology"><img src="${handleViteImages("uploads/image/20240427/Picture5.png")}" alt="" class="center"/></a>
    <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:115%;font-size:16px;font-family:"Aptos",sans-serif;'><br></p>
    <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:115%;font-size:16px;font-family:"Aptos",sans-serif;'><strong><span style="font-size:24px;line-height:115%;">&nbsp;</span></strong></p>
    <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:115%;font-size:16px;font-family:"Aptos",sans-serif;'><span style='font-size:19px;line-height:115%;font-family:"Verdana",sans-serif;color:black;background:white;'>OBiO Technology leads the way in gene and cell therapy as a pioneering Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO), dedicated to providing comprehensive solutions.</span></p>
    <img src="${handleViteImages("uploads/image/20240427/Picture6.png")}" alt="" class="center" />
    <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:115%;font-size:16px;font-family:"Aptos",sans-serif;text-align:center;'><br></p>
    <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:115%;font-size:16px;font-family:"Aptos",sans-serif;'><span style='font-size:19px;line-height:115%;font-family:"Verdana",sans-serif;color:black;background:white;'>&bull; &nbsp; &nbsp; &nbsp;Our state-of-the-art 830,000 sq.ft facility ensures global supply excellence.</span></p>
    <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:115%;font-size:16px;font-family:"Aptos",sans-serif;'><span style='font-size:19px;line-height:115%;font-family:"Verdana",sans-serif;color:black;background:white;'>&bull; &nbsp; &nbsp; &nbsp;Specializing in vectorology studies, functional genomics, and process and analytics development, we ensure Investigational New Drug (IND) readiness and support all phases of clinical and commercial manufacturing.</span></p>
    <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:115%;font-size:16px;font-family:"Aptos",sans-serif;'><span style='font-size:19px;line-height:115%;font-family:"Verdana",sans-serif;color:black;background:white;'>&bull; &nbsp; &nbsp; &nbsp;Guided by our mission to &quot;Enable Gene Therapy for Better Lives,&quot; we prioritize delivering top-tier services worldwide.</span></p>
    <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:115%;font-size:16px;font-family:"Aptos",sans-serif;'><span style='font-size:19px;line-height:115%;font-family:"Verdana",sans-serif;color:black;background:white;'>&bull; &nbsp; &nbsp; &nbsp;From laboratory to clinic, we continuously advance your products, making a positive impact on populations worldwide.</span></p>
    <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:115%;font-size:16px;font-family:"Aptos",sans-serif;'><span style='font-size:19px;line-height:115%;font-family:"Verdana",sans-serif;color:black;background:white;'>&bull; &nbsp; &nbsp; &nbsp;Our unwavering commitment ensures the delivery of high-quality CDMO services across the preclinical, IND, clinical, and commercial stages.</span></p>
    <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:115%;font-size:16px;font-family:"Aptos",sans-serif;'><span style='font-size:19px;line-height:115%;font-family:"Verdana",sans-serif;color:black;background:white;'>&bull; &nbsp; &nbsp; &nbsp;Our expertise spans plasmids, mRNA, AAV, LVV, Ad viral vectors, cell therapy (CAR-T, NK, Treg), as well as cutting-edge technologies like inducible viral vector packaging, ultralow endotoxin processes, and tissue-specific AAV variants.</span> <span style='font-size:19px;line-height:115%;font-family:"Verdana",sans-serif;color:black;background:white;'><br></span></p>
    <a href="https://obio-tech.com/cdmo"><img src="${handleViteImages("uploads/image/20240427/Picture7.png")}" alt="" class="center" /></a>
    <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:115%;font-size:16px;font-family:"Aptos",sans-serif;'><br></p>
    <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:115%;font-size:16px;font-family:"Aptos",sans-serif;'><span style='font-size:19px;line-height:115%;font-family:"Verdana",sans-serif;color:#0070C0;background:white;'>Your Trustful Partner in Research and Manufacturing for Gene and Cell Therapy</span></p>
    <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:115%;font-size:16px;font-family:"Aptos",sans-serif;'><span style='font-size:19px;line-height:115%;font-family:"Verdana",sans-serif;color:#0070C0;background:white;'>&nbsp;</span></p>
    <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:115%;font-size:16px;font-family:"Aptos",sans-serif;'><span style='font-size:19px;line-height:115%;font-family:"Verdana",sans-serif;color:#0070C0;background:white;'>Phone: +1 408 422 9864</span>&nbsp;</p>
    <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:115%;font-size:16px;font-family:"Aptos",sans-serif;'><span style='font-size:19px;line-height:115%;font-family:"Verdana",sans-serif;color:#0070C0;background:white;'>Email: OBiO.US@obiosh.com</span></p>
    <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:115%;font-size:16px;font-family:"Aptos",sans-serif;'><span style='font-size:19px;line-height:115%;font-family:"Verdana",sans-serif;color:black;background:white;'>&nbsp;</span></p>
    <div><a data-v-4896eafd="" href="https://www.linkedin.com/company/41870372" aria-label="Company LinkedIn"><svg data-v-4896eafd="" class="svg-inline--fa fa-linkedin fa-2xl footer-icon" aria-hidden="true" focusable="false" data-prefix="fab" data-icon="linkedin" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 448 512"><path class="" fill="currentColor" d="M416 32H31.9C14.3 32 0 46.5 0 64.3v383.4C0 465.5 14.3 480 31.9 480H416c17.6 0 32-14.5 32-32.3V64.3c0-17.8-14.4-32.3-32-32.3zM135.4 416H69V202.2h66.5V416zm-33.2-243c-21.3 0-38.5-17.3-38.5-38.5S80.9 96 102.2 96c21.2 0 38.5 17.3 38.5 38.5 0 21.3-17.2 38.5-38.5 38.5zm282.1 243h-66.4V312c0-24.8-.5-56.7-34.5-56.7-34.6 0-39.9 27-39.9 54.9V416h-66.4V202.2h63.7v29.2h.9c8.9-16.8 30.6-34.5 62.9-34.5 67.2 0 79.7 44.3 79.7 101.9V416z"></path></svg></a>&nbsp;
    <a data-v-4896eafd="" href="https://www.youtube.com/@obiotechnology" aria-label="Company YouTube"><svg data-v-4896eafd="" class="svg-inline--fa fa-youtube fa-2xl" aria-hidden="true" focusable="false" data-prefix="fab" data-icon="youtube" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 576 512"><path class="" fill="currentColor" d="M549.655 124.083c-6.281-23.65-24.787-42.276-48.284-48.597C458.781 64 288 64 288 64S117.22 64 74.629 75.486c-23.497 6.322-42.003 24.947-48.284 48.597-11.412 42.867-11.412 132.305-11.412 132.305s0 89.438 11.412 132.305c6.281 23.65 24.787 41.5 48.284 47.821C117.22 448 288 448 288 448s170.78 0 213.371-11.486c23.497-6.321 42.003-24.171 48.284-47.821 11.412-42.867 11.412-132.305 11.412-132.305s0-89.438-11.412-132.305zm-317.51 213.508V175.185l142.739 81.205-142.739 81.201z"></path></svg></a>&nbsp;
    <a data-v-4896eafd="" href="https://www.facebook.com/profile.php?id=61555811491695" aria-label="Company Facebook"><svg data-v-4896eafd="" class="svg-inline--fa fa-facebook fa-2xl" aria-hidden="true" focusable="false" data-prefix="fab" data-icon="facebook" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512"><path class="" fill="currentColor" d="M512 256C512 114.6 397.4 0 256 0S0 114.6 0 256C0 376 82.7 476.8 194.2 504.5V334.2H141.4V256h52.8V222.3c0-87.1 39.4-127.5 125-127.5c16.2 0 44.2 3.2 55.7 6.4V172c-6-.6-16.5-1-29.6-1c-42 0-58.2 15.9-58.2 57.2V256h83.6l-14.4 78.2H287V510.1C413.8 494.8 512 386.9 512 256h0z"></path></svg></a></div></div>`
  },
  {
    id: 7,
    type: "event",
    title: `Join US @ Sino-American Pharmaceutical Professionals Association (SAPA) Meeting in Boston! Exploring the Future of Cell and Gene Therapy`,
    time: "March 7th 2024",
    content: `Waltham, MA United States`,
    eventTime: 'March 30, 2024',
    location: '300 3rd Ave, Waltham, MA 02451',
    html: `<div class="Insights-detail-text text">
    <span style="font-size:14px;">Join US @ Sino-American Pharmaceutical Professionals Association (SAPA) Meeting in Boston! Exploring the Future of Cell and Gene Therapy</span><br>
<br>
<span style="font-size:14px;"> Date: March 30th, 2024.Saturday 1pm-5pm</span><br>
<span style="font-size:14px;"> Location: 300 3rd Ave, Waltham ,MA 02451</span><br>
<br>
<span style="font-size:14px;"> Details:</span><br>
<span style="font-size:14px;"> Dive deep into the world of Cell and Gene Therapy (CGT)</span><br>
<span style="font-size:14px;"> Explore the latest advancements and breakthroughs</span><br>
<span style="font-size:14px;"> Collaborate with experts in the field</span><br>
<span style="font-size:14px;"> Strategize for future innovation</span><br>
<br>
<span style="font-size:14px;"> Registration link：https://lnkd.in/gvdypBiF</span><br>
<p>
<span style="font-size:14px;"> For more information, contact Sabrina at sabrina.he@obiosh.com</span> 
</p>
<p>
<span style="font-size:14px;"><br>
</span>
</p>
<p>
<img src="${handleViteImages("uploads/image/20240308/20240308123702_46230.jpg")}" alt=""> 
</p>                </div>`,
  },
  {
    id: 1,
    title: `Cell & Gene meeting on the Mesa`,
    time: "Oct 10-12 2023",
    content: `Carlsbad, CA, United States`,
    html: `<div class="Insights-detail-text text"><div class="font-size20 color666">Carlsbad, CA, United States</div></div>`,
  },
  {
    id: 2,
    type: "event",
    title: `BioProcess International Conference & Exhibition`,
    time: "Sep 18-21 2023",
    content: `Boston, MA`,
    html: `<div class="Insights-detail-text text"><p>Related Links:</p>
	<p>
	<a href="https://informaconnect.com/cell-therapy-bioprocessing/" target="_blank">https://informaconnect.com/cell-therapy-bioprocessing/</a>
</p></div>`,
  },
  {
    id: 3,
    type: "event",
    title: `ASGCT 26th Annual Meeting`,
    time: "May 16-20 2023",
    content: `Los Angeles, CA`,
    html: `<div class="Insights-detail-text text">
    <p>
      <span style="font-size: 18px">Los Angeles, CA</span>
    </p>
    <p>
      <span style="font-size: 18px"><br /> </span>
    </p>
    <p>Related Links:</p>
    <p>
      <a href="https://asgct.org/" target="_blank"
        >https://annualmeeting.asgct.org/</a
      >
    </p>
  </div>`,
  },

  {
    id: 4,
    type: "event",
    time: "15th-16th Apr. ,2022",
    title: "SAPA-GP 2022 Annual Conference (Hybrid)",
    content: "King of Prussia, PA",
    html: `<div class="Insights-detail-text text">
    <p>
      <span style="font-size: 18px">Los Angeles, CA</span>
    </p>
    <p>
      <span style="font-size: 18px"><br /> </span>
    </p>
    <p>Related Links:</p>
    <p>
      <a href="https://asgct.org/" target="_blank"
        >https://annualmeeting.asgct.org/</a
      >
    </p>
  </div>`,
  },
  {
    id: 5,
    type: "event",
    time: "16th-19th May ,2022",
    title: "ASGCT 25th Annual Meeting",
    content: "Washington, D.C.",
    html: `<div class="Insights-detail-text text">
    <span style="font-size: 18px; line-height: 2">WASHINGTON, D.C.</span
    ><br />
    <br />
    <span style="font-size: 18px; line-height: 2">Related Links:</span><br />
    <span style="font-size: 18px; line-height: 2"
      ><a href="https://annualmeeting.asgct.org/" target="_blank"
        >https://annualmeeting.asgct.org/</a
      ></span
    ><br />
    <span style="font-size: 18px; line-height: 2"></span>
  </div>`,
  },
  {
    id: 6,
    type: "event",
    time: "15th-16th Jul. ,2022",
    title: "China Oncolytic Virus Conference 2022 (Hybrid)",
    content: "Shanghai, China",
    html: `<div class="Insights-detail-text text">
    <span style="font-size: 18px; line-height: 2">SHANGHAI, China</span><br />
    <br />
    <span style="font-size: 18px; line-height: 2">Related Links:</span><br />
    <span style="font-size: 18px; line-height: 2"
      ><a
        href="https://www.bagevent.com/event/8106755?code=061OMvGa1j6bRC0K6bHa145GHz1OMvGK&amp;state=STATE"
        target="_blank"
        >https://www.bagevent.com/event/8106755?code=061OMvGa1j6bRC0K6bHa145GHz1OMvGK&amp;state=STATE</a
      ></span
    ><br />
    <span style="font-size: 18px; line-height: 2"></span>
  </div>`,
  },
]);
